documents incorporated reference document part proxy statement annual meeting shareholders held may filed part iii securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include two operating segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers company previously healthcare services segment provided services solutions focused engagement health analytics clinical services improve value care delivered patients company divested remaining businesses segment first quarter company previously alliances segment primarily included activity companys relationship astrazeneca lp related sales nexium prilosec concluded product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners planned spinoff womens health biosimilars established brands new company february merck announced intention spinoff spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders distribution expected qualify taxfree company shareholders us federal income tax purposes established brands included transaction consist dermatology nonopioid pain management respiratory select cardiovascular products including zetia ezetimibe vytorin ezetimibesimvastatin well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned organon development capabilities initially focused latestage development lifecycle management expected time develop research capabilities selected therapeutic areas spinoff expected completed late second quarter subject market certain conditions see risk factors risks related proposed spinoff organon table contents product sales total company sales including sales companys top pharmaceutical products well sales animal health products follows millions total sales pharmaceutical keytruda januviajanumet gardasilgardasil proquadmmr iivarivax bridion pneumovax isentressisentress hd simponi rotateq alliance revenue lynparza implanonnexplanon zetiavytorin alliance revenue lenvima animal health livestock companion animals revenues alliance revenue represents mercks share profits product sales net cost sales commercialization costs revenues primarily comprised thirdparty manufacturing sales miscellaneous corporate revenues including revenue hedging activities pharmaceutical pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices certain products within companys franchises follows oncology keytruda pembrolizumab companys antipd programmed death receptor therapy monotherapy treatment certain patients cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal cancer gastric gastroesophageal junction adenocarcinoma head neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc nonsmallcell lung cancer nsclc smallcell lung cancer sclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr cancer including msihdmmr colorectal cancer primary mediastinal large bcell lymphoma pmbcl tumor mutational burdenhigh tmbh cancer urothelial carcinoma including nonmuscle invasive bladder cancer keytruda also approved treatment certain patients combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination chemotherapy triplenegative breast cancer combination axitinib renal cell carcinoma combination lenvatinib endometrial carcinoma emend aprepitant prevention certain chemotherapyinduced nausea vomiting addition company recognizes alliance revenue related sales lynparza olaparib oral poly adpribose polymerase parp inhibitor certain types advanced ovarian breast pancreatic prostate cancers lenvima lenvatinib certain types thyroid cancer hepatocellular carcinoma combination everolimus certain patients renal cell carcinoma combination keytruda certain patients endometrial carcinoma vaccines gardasil human papillomavirus quadrivalent types vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccines help prevent certain diseases table contents caused certain types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children vaqta hepatitis vaccine inactivated indicated prevention disease caused hepatitis virus persons months age older hospital acute care bridion sugammadex injection medication reversal two types neuromuscular blocking agents used surgery noxafil posaconazole antifungal agent prevention certain invasive fungal infections prevymis letermovir prophylaxis cytomegalovirus cmv reactivation disease adult cmvseropositive recipients r allogeneic hematopoietic stem cell transplant primaxin imipenem cilastatin injection antibiotic treatment certain bacterial infections cancidas caspofungin acetate injection antifungal agent treatment certain fungal infections invanz ertapenem injection antibiotic treatment certain bacterial infections cubicin daptomycin injection antibiotic treatment certain bacterial infections zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain bacterial infections immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases remicade infliximab treatment inflammatory diseases company markets europe russia turkey neuroscience belsomra suvorexant orexin receptor antagonist indicated treatment insomnia characterized difficulties sleep onset andor sleep maintenance virology isentressisentress hd raltegravir hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection zepatier elbasvir grazoprevir treatment adult patients chronic hepatitis c virus hcv genotype gt gt infection ribavirin certain patient populations cardiovascular zetia ezetimibe marketed ezetrol countries outside united states vytorin ezetimibesimvastatin marketed inegy outside united states atozet ezetimibe atorvastatin marketed outside united states rosuzet ezetimibe rosuvastatin marketed outside united states cholesterol modifying medicines adempas riociguat cardiovascular drug treatment pulmonary arterial hypertension diabetes januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes womens health implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshaped subdermal contraceptive implant nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product animal health animal health segment discovers develops manufactures markets wide range veterinary pharmaceuticals vaccines health management solutions services well extensive suite digitally connected identification traceability monitoring products principal products segment include livestock products nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorders cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory table contents drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiencies beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type killed baculovirus vector vaccine lines infectious diseases swine nobilisinnovax live mareks disease vector vaccine lines poultry paracox coccivac coccidiosis vaccines exzolt systemic treatment poultry red mite infestations slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor florfenicol antibiotic farmraised fish allflex livestock intelligence solutions animal identification monitoring traceability companion animal products bravecto line oral topical parasitic control products including original bravecto fluralaner products dogs cats last weeks bravecto fluralaner onemonth monthly product dogs bravecto plus fluralanermoxidectin twomonth product cats sentinel line oral parasitic products dogs including sentinel spectrum milbemycin oxime lufenuron praziquantel sentinel flavor tabs milbemycin oxime lufenuron optimmune cyclosporine ophthalmic ointment nobivac vaccine lines flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabetes mellitus treatment dogs cats panacur fenbendazolesafeguard fenbendazole broad spectrum anthelmintic dewormer use many animals regumate altrenogest fertility management horses prestige vaccine line horses scalibor deltamethrinexspot protecting bites fleas ticks mosquitoes sandflies sure petcare products companion animal identification wellbeing including microchip pet recovery system home discussion sales companys products see item managements discussion analysis financial condition results operations product approvals set forth summary significant product approvals received company product date approval us food drug administration fda approved dificid oral suspension dificid tablets dificid january treatment clostridioides formerly clostridium difficileassociated diarrhea children aged six months older chinas national medical products administration nmpa granted expanded approval gardasil gardasil november use girls women years age japans ministry health labour welfare mhlw approved additional indication dosage administrations gardasil marketed silgard prevention anal cancer squamous cell cancer precursor lesions anal intraepithelial neoplasia grade caused hpv types december individuals years older genital warts condyloma acuminate men years older japans pharmaceuticals medical devices agency pmda approved gardasil use girls gardasil women years older prevention cervical cancer certain cervical vaginal vulvar july precancers genital warts caused hpv types covered vaccine fda granted accelerated approval expanded indication gardasil prevention june oropharyngeal head neck cancers caused hpv types table contents nmpa approved keytruda monotherapy firstline treatment patients metastatic unresectable recurrent hnscc whose tumors express pdl combined positive score cps december determined fully validated test fda granted accelerated approval keytruda combination chemotherapy patients november locally recurrent unresectable metastatic triplenegative breast cancer whose tumors express pdl cps fda approved expanded label keytruda monotherapy treatment adult patients october relapsed refractory chl pmda approved keytruda use additional recommended dosage mg every six weeks qw administered intravenous infusion minutes across adult indications including august keytruda monotherapy combination therapy pmda approved keytruda treatment patients whose tumors pdlpositive radically unresectable advanced recurrent esophageal squamous cell carcinoma escc august progressed chemotherapy fda approved keytruda monotherapy firstline treatment patients unresectable june metastatic msih dmmr colorectal cancer keytruda fda approved keytruda monotherapy treatment patients recurrent metastatic cscc june curable surgery radiation nmpa approved keytruda monotherapy treatment patients locally advanced metastatic escc whose tumors express pdl cps determined fully validated test june following failure one prior line systemic therapy fda granted accelerated approval keytruda monotherapy treatment adult pediatric patients unresectable metastatic tmbh mutationsmegabase mutmb solid tumors determined fdaapproved test progressed following prior treatment june satisfactory alternative treatment options fda granted accelerated approval keytruda use additional recommended dose mg april every six weeks qw approved adult indications fda approved keytruda patients bacillus calmetteguerin bcgunresponsive highrisk non muscle invasive bladder cancer carcinoma situ without papillary tumors ineligible january elected undergo cystectomy fda approved kinase inhibitor koselugo treatment pediatric patients two years age koselugo april older neurofibromatosis type nf symptomatic inoperable plexiform neurofibromas pn lenvima november nmpa approved lenvima monotherapy treatment differentiated thyroid cancer table contents pmda approved lynparza treatment patients brca genemutated brcam castration december resistant prostate cancer distant metastasis pmda approved lynparza maintenance treatment platinumbased chemotherapy patients december brcam curatively unresectable pancreas cancer pmda approved lynparza maintenance treatment firstline chemotherapy containing bevacizumab genetical recombination patients homologous recombination repair deficient december hrd ovarian cancer european commission ec approved lynparza maintenance treatment adult patients advanced figo stages iii iv highgrade epithelial ovarian fallopian tube primary peritoneal cancer response complete partial following completion firstline platinum based chemotherapy combination bevacizumab whose cancer associated hrd november positive status defined either breast cancer susceptibility gene brca mutation andor genomic instability ec approved lynparza monotherapy treatment adult patients metastatic castration lynparza resistant prostate cancer mcrpc brca mutations germline andor somatic november progressed following prior therapy included new hormonal agent ec approved lynparza monotherapy maintenance treatment adult patients germline brca mutations metastatic adenocarcinoma pancreas progressed minimum weeks platinum treatment within firstline chemotherapy regimen july fda approved lynparza treatment adult patients deleterious suspected deleterious germline somatic homologous recombination repair hrr genemutated mcrpc determined fdaapproved test progressed following prior treatment enzalutamide may abiraterone fda approved lynparza combination bevacizumab firstline maintenance treatment adult patients advanced epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbased chemotherapy whose cancer associated may hrd positive status defined either deleterious suspected deleterious brca mutation andor genomic instability determined fdaapproved test fda approved recarbrio treatment patients years age older hospitalacquired recarbrio june bacterial pneumonia ventilatorassociated bacterial pneumonia habpvabp steglatro july nmpa approved steglatro mg tablets treatment type diabetes dificid us canada trademark cubist pharmaceuticals llc indirect whollyowned subsidiary merck sharp dohme corp july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza koselugo commercialized promoted worldwide except japan collaboration pfizer inc table contents competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result payment royalties recognition impairment charge respect intangible assets associated certain products pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company wellpositioned compete search technological innovations company active acquiring marketing products external alliances licensing arrangements collaborations refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products well competitors products effective promotional efforts frequent introduction generic products competitors health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access united states united states federal state governments many years pursued methods reduce cost drugs vaccines pay example federal state laws require company pay specified rebates medicines reimbursed medicaid provide discounts medicines purchased certain state federal entities department defense veterans affairs public health service entities hospitals serving disproportionate share low income uninsured patients health care programs united states enacted major health care reform legislation aca various insurance market reforms since advanced state federal insurance exchanges launched respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay cost medicine including biosimilar products medicare part beneficiaries medicare part coverage gap ie socalled donut hole increased beginning result balanced budget act merck recorded approximately million million million reduction revenue respectively related donut hole provision also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee set billion fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded approximately million million million costs within selling general administrative table contents expenses respectively annual health care reform fee february centers medicare medicaid services cms issued medicaid rebate final rule implemented provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs recently although cms previously declined define constitutes product line extension beyond statutory definition cms issued new rule december significantly expand definition term line extension january include broad range products including products reflecting new strengths dosage forms release mechanisms routes administration expanded definition increase number drugs subject higher medicaid rebate effective january final rule also changes way manufacturers must calculate best price relation certain patient support programs including coupons also may result increase companys medicaid rebates impact provisions final rule could adversely impact companys business cash flow results operations financial condition prospects patient protection affordable care act significant uncertainty future aca particular health care laws general united states december texas federal district court struck aca grounds individual health insurance mandate unconstitutional united states supreme court heard arguments case november company participating health care debate monitoring proposed changes could affect business company unable predict likelihood changes aca depending nature changes aca actions could material adverse effect companys business cash flow results operations financial condition prospects legislative changes addition legislative changes proposed adopted united states since aca enacted number states passed pharmaceutical price cost transparency laws laws typically require manufacturers report certain product price information financial data state laws also require manufacturers provide advance notification price increases company expects states continue focus pharmaceutical price transparency focus continue exert pressure product pricing drug pricing company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins including united states practices managed care organizations federal state exchanges institutional governmental purchasers ii federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca november department health human services office inspector general oig issued final rule would effective january eliminate antikickback statute safe harbor rebates paid medicare part plans pharmacy benefit managers pbms behalf plans company anticipate effects change way currently contracts new framework could significantly alter way business part plan sponsors pbms behalf plans rulemaking also established effective january new safe harbor point sale discounts pharmacy counter new safe harbor certain services arrangements pharmaceutical manufacturers pbms cms also recently issued interim final rule mfn rule alters physicians reimbursed medicare program physician administered drugs pursuant mfn rule intended effective january rather use current average sales price aspbased payment framework certain physicianadministered drugs mfn rule would institute new pricing system certain prescription drugs biologic products covered medicare part b medicare would reimburse favored nation price meaning lowest price adjusting volume differences gross domestic product top part b reimbursed products includes keytruda sold member countries organisation economic cooperation development oecd several organizations including two table contents trade groups merck member filed suit challenging regulation lawsuits remain pending preliminary injunction entered one cases time company predict certainty mfn rule go effect implementation mfn rule could material adverse effect companys business cash flow results operations financial condition prospects fda also recently issued rulemaking allowing commercial importation certain prescription drugs canada fdaauthorized time limited programs sponsored states native american tribes recognized rule certain future circumstances pharmacists wholesalers fda also recently released final guidance industry detailing procedures drug manufacturers import fdaapproved prescription drug biological combination products manufactured abroad authorized intended sale foreign country trade organization merck member brought suit remains pending federal district court challenging commercial importation rule proposed changes could material adverse effect companys business cash flow results operations financial condition prospects changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures example health care reform contributed increase number patients medicaid program sales pharmaceutical products subject substantial rebates pharmaceutical industry also could considered potential source savings via legislative administrative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls active consideration drugpricing related legislation last congress remains uncertain proposals may included part future federal legislative proposals would directly indirectly affect company us private sector consolidation integration among health care providers major factor competitive marketplace pharmaceutical products health plans pbms consolidating fewer larger entities thus enhancing purchasing strength importance private thirdparty insurers well governments employ formularies control costs negotiating discounted prices exchange formulary inclusion failure obtain timely adequate pricing formulary placement mercks products obtaining placement unfavorable pricing could adversely affect revenue addition formulary tier copay differentials private health insurance companies selfinsured employers raising copayments required beneficiaries particularly branded pharmaceuticals biotechnology products private health insurance companies also increasingly imposing utilization management tools clinical protocols requiring prior authorization branded product generic product available requiring patient first fail one generic products permitting access branded medicine management tools also used treatment areas payor taken position multiple branded products therapeutically comparable us payor market concentrates drugs become available generic form pharmaceutical companies may face greater pricing pressure private thirdparty payors order provide information companys pricing practices company annually posts website pricing transparency report united states report provides companys average annual list price net price increases average discounts across companys us portfolio dating back companys gross us sales reduced result rebates discounts returns european union efforts toward health care cost containment remain intense european union eu company faces competitive pricing pressure resulting generic biosimilar drugs addition majority countries eu attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs reference pricing may either compare products prices markets external reference pricing compare products price products national class internal reference pricing authorities use price data set new local prices brandname drugs including companys drugs guidelines examining reference pricing usually set local markets changed table contents pursuant local regulations eu member states established freepricing systems regulate pricing drugs profit control plans others seek negotiate set prices based costeffectiveness product assessment whether offers therapeutic benefit products relevant class downward pressure health care costs general particularly prescription drugs become intense result increasingly high barriers erected entry new products eu member states crossborder imports lowpriced markets also exert competitive pressure may reduce pricing within eu member state additionally eu member states power restrict range pharmaceutical products national health insurance systems provide reimbursement eu pricing reimbursement plans vary widely member state member state eu member states provide drug products may marketed reimbursement price agreed eu member states may require completion additional studies compare cost effectiveness particular product candidate already available therapies socalled health technology assessments hta order obtain reimbursement pricing approval hta pharmaceutical products becoming increasingly common part pricing reimbursement procedures eu member states hta process governed national laws countries involves assessment costeffectiveness public health impact therapeutic impact andor economic social impact use given pharmaceutical product national health care system individual country conducted ultimately hta measures added value new health technology compared existing ones outcome htas regarding specific pharmaceutical products often influence pricing reimbursement status granted pharmaceutical products regulatory authorities individual eu member states negative hta one companys products may mean product reimbursable may force company reduce reimbursement price offer discounts rebates negative hta leading recognized hta body could also undermine companys ability obtain reimbursement relevant product outside jurisdiction example eu member states yet developed hta mechanisms may rely extent hta performed countries developed hta framework inform pricing reimbursement decisions hta procedures require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement obtain reimbursement pricing approval eu member states company may required conduct studies compare cost effectiveness companys product candidates therapies considered local standard care assurance eu member state allow favorable pricing reimbursement market access conditions companys products feasible conduct additional costeffectiveness studies required brexit united kingdom uk held referendum voters approved exit eu commonly referred brexit result referendum subsequent negotiations uk left eu january transitional period applied january december period eu uk operated uk eu member state uk continued participate eu customs union allowing freedom movement people goods announced december eu uk agreed trade cooperation agreement tca tca sets new arrangements trade goods including medicines vaccines allows goods continue flow eu uk december council eu adopted decision sign tca tca provisionally applied january uk eu signed tca december order tca ratified formally come effect council eu must unanimously approve tca european parliament must consent company believes occur result tca company believes operations materially adversely affected brexit table contents japan japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines furthermore government order repricings specific products determines use product exceed certain thresholds defined applicable repricing rules next governmentmandated price reduction occur april expected impact many company products china companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys current inline products absence trade impediments adverse pricing controls recent years chinese government introduced implemented number structural reforms accelerate shift innovative products reduce costs since multiple new policies introduced government improve access new innovation reduce complexity regulatory filings accelerate review approval process led significant increase number new products approved year additionally chinese government updated national reimbursement drug list nrdl first time eight years mechanism drugs added list evolves inclusion may require price negotiation could impact outlook market selected brands drugs added nrdl doubledigit price reductions pricing pressure always existed china health care reform increased pressure part due acceleration generic substitution volume based procurement vbp government implemented vbp program tendering process mature products generic substitutes generic quality consistency evaluation approval mature products entered first three rounds vbp average price reduction company expects vbp semiannual process significant impact mature products moving forward emerging markets companys focus emerging markets addition china continued governments many emerging markets also focused constraining health care costs enacted price controls measures impacting intellectual property including exceptional cases threats compulsory licenses aim put pressure price innovative pharmaceuticals result constrained market access innovative medicine company anticipates pricing pressures market access challenges continue future varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability changes trade sanctions embargoes significant currency fluctuation controls financial crises limited changing availability funding health care credit worthiness health care partners hospitals due covid developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization table contents business practices better meet customer needs believes wellpositioned respond evolving health care environment market forces regulation pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market united states time fda committed expediting development review products bearing breakthrough therapy designation accelerated regulatory review process medicines designation fda also undertaken efforts bring generic competition market efficiently timely manner eu adopted directives legislation concerning classification approval marketing labeling advertising manufacturing wholesale distribution integrity supply chain pharmacovigilance safety monitoring medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states particular eu regulators may approve products subject number postauthorization conditions examples typical postauthorization commitments include additional pharmacovigilance conduct clinical trials establishment patient registries physician patient education controlled distribution prescribing arrangements non compliance postauthorization conditions pharmacovigilance obligations lead regulatory action including variation suspension withdrawal marketing authorizations enforcement regulatory actions including imposition financial penalties companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access medicines vaccines quality health care around world companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition innovative social investments including philanthropic programs impact investing merck also helping strengthen health systems build capacity particularly underresourced communities merck patient assistance program provides medicines adult vaccines free people united states prescription drug health insurance coverage without companys assistance afford merck medicines vaccines merck funded merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth merck also provided funds merck foundation independent grantmaking organization partnered variety organizations dedicated improving global health privacy data protection company subject significant number privacy data protection laws regulations globally many place restrictions companys ability transfer access use personal data across business legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including eu general data protection regulation gdpr went effect may imposes penalties global revenue table contents gdpr related implementing laws individual eu member states govern collection use personal health data personal data eu gdpr increased responsibility liability relation personal data company processes also imposes number strict obligations restrictions ability process includes collection analysis transfer personal data including health data clinical trials adverse event reporting gdpr also includes requirements relating consent individuals personal data relates information provided individuals prior processing personal data personal health data notification data processing obligations national data protection authorities security confidentiality personal data gdpr prohibits transfer personal data countries outside eu considered ec provide adequate level data protection including united states except data controller meets specific requirements following schrems ii decision court justice european union july considerable uncertainty permissibility international data transfers gdpr light implications decision company may face difficulties regarding transfer personal data eu third countries failure comply requirements gdpr related national data protection laws eu member states may result significant monetary fines administrative penalties well civil liability claims individuals whose personal data processed data protection authorities different eu member states may still implement certain variations enforce gdpr national data protection laws differently introduce additional national regulations guidelines adds complexity processing personal data eu guidance developed eu level national level individual eu member states concerning implementation compliance practices often updated otherwise revised moreover growing trend towards required public disclosure clinical trial data eu adds complexity obligations relating processing health data clinical trials failing comply obligations could lead government enforcement actions significant penalties company harm reputation adversely impact business operating results uncertainty regarding interplay different regulatory frameworks adds complexity company faces regard data protection regulation additional laws regulations enacted united states california consumer privacy act europe asia latin america increased enforcement litigation activity united states developed markets well increased regulatory cooperation among privacy authorities globally company adopted comprehensive global privacy program manage evolving risks facilitate transfer personal information across international borders distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pbms institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers patents trademarks licenses patent protection considered aggregate material importance companys marketing products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant current us patent law table contents provides additional patent term periods patented product regulatory review fda eu also provides additional six months pediatric market exclusivity attached products supplementary protection certificate spc japan provides additional term pediatric studies attached market exclusivity unrelated patent term patent portfolios developed products introduced company normally provide market exclusivity company following key patent protection united states eu japan china including potential patent term extensions pte spcs indicated following marketed products product year expiration us year expiration eu year expiration japan year expiration china januvia janumet na janumet xr na na isentress simponi na na na lenvima pending pte patents spcs adempas bridion pending pte expired nexplanon device device na bravecto pending pte patents spcs gardasil expired na gardasil patents spcs na keytruda patents spcs lynparza pending pte patents spcs zerbaxa patents spcs pending pte na sivextro patents spcs belsomra na na prevymis pending pte patents spcs na segluromet pending pte patents spcs na na steglatro pending pte patents spcs na steglujan pending pte patents spcs na na verquvo pending pte na na na delstrigo pending pte patents spcs na na pifeltro pending pte patents spcs recarbrio pending pte na na na note compound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities na currently marketing approval table contents eu date represents expiration date following five countries france germany italy spain united kingdom major eu markets spc applications filed granted major eu markets patent expiry date spc expiry date listed pte system japan allows patent extended provided later approval directed different indication previous approval may result multiple pte approvals given patent expiration date eligible months pediatric exclusivity company marketing rights us japan china expiration distribution agreement janssen pharmaceuticals inc part global strategic oncology collaboration eisai commercialized worldwide collaboration bayer ag part global strategic oncology collaboration astrazeneca commercialized promoted worldwide except japan collaboration pfizer inc company marketing rights japan company marketing rights eu japan china company also following key us patent protection drug candidates review phase development currently anticipated phase drug candidate year expiration us mk gefapixant v pneumoconjugate vaccine vaccine composition mk cdfc mka islatravirdoravirine mk belzutifan unless otherwise noted patents charts compound patents patent may subject future patent term restoration five years six month pediatric market exclusivity either may available addition depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product also regulatory exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity compounds patent estate united states data protection generally runs five years first marketing approval new chemical entity extended seven years orphan drug indication years first marketing approval biological product expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities table contents worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program december approximately people employed companys research activities company prioritizes research development efforts focuses candidates believes represent breakthrough science make difference patients payers company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed ensuring externally sourced programs remain important component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases metabolic diseases infectious diseases neurosciences respiratory diseases vaccines development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologic believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing table contents assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase studies doseranging studies finally phase trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies united states fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review pursuant prescription drug user fee act v pdufa fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete review timelines determined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving crl resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review one special designations granted given application ie product designated breakthrough therapy may also eligible priority review due covid public health crisis united states secretary health human services exercised statutory authority determine public health emergency exists declare circumstances justify emergency use drugs biological products authorized fda effect declaration enables fda issue emergency use authorizations euas permitting distribution use specific medical products absent ndabla submission approval including products treat prevent diseases conditions caused sarscov virus subject terms euas fda must make certain findings grant eua including reasonable believe based totality evidence drug biologic may effective known potential benefits used terms eua outweigh known potential risks additionally fda must find adequate approved available alternative emergency use primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products table contents particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure eu member states outside united states eu company submits marketing applications national regulatory authorities examples ministry health labour welfare japan national medical products administration china health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline many markets approval times longer regulatory authority requires approval major market united states eu issuance certificate pharmaceutical product market initiating local review process research development update company currently several candidates regulatory review united states internationally latestage clinical development mka combination relebactum betalactamase inhibitor imipenemcilastatin carbapenem antibiotic review japan treatment bacterial infection mka approved fda marketed united states recarbrio mk vericiguat orally administered soluble guanylate cyclase sgc stimulator review eu japan reduce risk cardiovascular death heart failure hospitalization following worsening heart failure event patients symptomatic chronic heart failure reduced ejection fraction combination heart failure therapies applications based results phase victoria trial vericiguat approved fda january marketed united states verquvo vericiguat jointly developed bayer bayer commercialize vericiguat territories outside united states approved mk selumetinib review eu treatment pediatric patients two years age older neurofibromatosis type nf symptomatic inoperable plexiform neurofibromas pn based positive results national cancer institute cancer therapy evaluation program sponsored phase sprint stratum trial selumetinib approved fda april marketed united states koselugo selumetinib jointly developed commercialized astrazeneca globally v investigational valent pneumococcal conjugate vaccine priority review fda prevention invasive pneumococcal disease adults years age older fda set pdufa date july ema also reviewing application licensure v adults additionally company several ongoing phase trials evaluating v pediatric patients v previously received breakthrough therapy designation fda prevention invasive pneumococcal disease pediatric patients weeks years age adults years age older company involved litigation challenging validity several pfizer inc patents relate pneumococcal vaccine technology united states several foreign jurisdictions keytruda antipd therapy approved treatment many cancers clinical development expanded indications approvals result broad clinical development program currently consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including biliary tract cervical colorectal cutaneous squamous cell endometrial esophageal estrogen receptor positive breast cancer gastric glioblastoma head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma nonsmallcell lung smallcell lung melanoma mesothelioma ovarian prostate renal triplenegative breast urothelial many currently phase clinical development trials planned cancers table contents keytruda combination chemotherapy review eu treatment locally recurrent unresectable metastatic triple negative breast cancer tnbc adults whose tumors express pdl cps received prior chemotherapy metastatic disease based results keynote trial keytruda approved indication accelerated approval based progressionfree survival pfs fda november keytruda combination chemotherapy also review japan treatment patients locally recurrent unresectable metastatic tnbc based data keynote trial july fda accepted standard review supplemental bla keytruda treatment patients highrisk earlystage tnbc combination chemotherapy neoadjuvant preoperative treatment single agent adjuvant postoperative treatment surgery application based data first second interim analyses keynote trial february fdas oncologic drugs advisory committee odac discussed companys supplemental bla keytruda voted regulatory decision deferred data available phase keynote trial study met one dual primary endpoints pathological complete response continuing evaluate eventfree survival odac provides fda independent expert advice recommendations marketed investigational medicines use treatment cancer fda bound committees guidance takes advice consideration pdufa date application march next interim analysis calendardriven data expected third quarter february merck announced committee medicinal products human use chmp ema adopted positive opinion recommending approval expanded label keytruda monotherapy treatment adult pediatric patients aged years older relapsed refractory chl failed earlier line therapy recommendation based results pivotal phase keynote trial keytruda monotherapy demonstrated significant improvement pfs compared brentuximab vedotin commonly used treatment recommendation also based supportive data updated analysis keynote trial supported ec approval keytruda treatment adult patients relapsed refractory chl chmps recommendation reviewed ec marketing authorization eu keytruda approved indication fda october keytruda also review monotherapy firstline treatment adult patients metastatic msih dmmr colorectal cancer japan based result keynote trial keytruda approved indication fda june eu january january fda accepted supplemental bla seeking use keytruda treatment patients locally advanced cscc curable surgery radiation based results keynote trial fda set pdufa date september december fda accepted granted priority review supplemental bla keytruda combination chemotherapy firstline treatment patients locally advanced unresectable metastatic carcinoma esophagus gastroesophageal junction supplemental bla based data pivotal phase keynote trial keytruda plus chemotherapy demonstrated significant improvements primary endpoints overall survival os pfs versus chemotherapy patients regardless pdl expression status tumor histology data presented european society medical oncology esmo virtual congress fda set pdufa date april december chmp ema announced start procedure extend indication include combination chemotherapy firstline treatment locally advanced unresectable metastatic carcinoma esophagus negative gastroesophageal junction adenocarcinoma adults keytruda based results keynote keytruda also review indication japan keytruda also received breakthrough therapy designation fda february combination keytruda padcev enfortumab vedotinejfv firstline setting treatment patients unresectable locally advanced metastatic urothelial cancer eligible cisplatin containing chemotherapy fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints table contents january merck announced firsttime data phase keynote study evaluating keytruda combination ipilimumab yervoy compared keytruda monotherapy firstline treatment patients metastatic nsclc without egfr alk genomic tumor aberrations whose tumors express pdl tumor proportion score results study showed addition ipilimumab keytruda improve os pfs added toxicity compared keytruda monotherapy patients results presented presidential symposium iaslc world conference lung cancer hosted international association study lung cancer january published journal clinical oncology previously announced november study discontinued due futility based recommendation independent data monitoring committee dmc determined benefitrisk profile keytruda combination ipilimumab support continuing trial dmc also advised patients study discontinue treatment ipilimumabplacebo february mercks announced phase keynote trial evaluating keytruda versus standard care treatment capecitabine gemcitabine docetaxel treatment recurrent metastatic nasopharyngeal cancer meet primary endpoint os full results presented future medical meeting may merck eisai presented data analyses two phase trials evaluating keytruda plus lenvima american society clinical oncology asco annual meeting keytruda plus lenvima combination demonstrated clinically meaningful objective response rates orr keynotestudy trial patients unresectable hcc prior systemic therapy keynotestudy trial patients metastatic clear cell renal cell carcinoma ccrcc progressed following immune checkpoint inhibitor therapy july merck eisai announced fda issued crl regarding mercks eisais applications seeking accelerated approval first line treatment patients unresectable hcc based trial showed clinically meaningful efficacy singlearm setting data supported breakthrough therapy designation granted fda july ahead pdufa action dates mercks eisais applications another combination therapy approved based randomized controlled trial demonstrated improvement os versus standardofcare treatment consequently crl stated mercks eisais applications provide evidence keytruda combination lenvima represents meaningful advantage available therapies treatment unresectable metastatic hcc prior systemic therapy advanced disease since applications keynotestudy longer meet criteria accelerated approval companies plan work fda take appropriate next steps include conducting well controlled clinical trial demonstrates substantial evidence effectiveness clinical benefit combination leap phase trial evaluating keytruda plus lenvima combination firstline treatment advanced hcc currently underway fully enrolled crl impact current approved indications keytruda lenvima february merck eisai announced first presentation new investigational data pivotal phase clear study keynote study genitourinary cancers symposium asco gu published simultaneously new england journal medicine trial evaluated combinations keytruda plus lenvima lenvima plus everolimus versus sunitinib firstline treatment patients advanced rcc keytruda plus lenvima demonstrated statistically significant clinically meaningful improvements pfs os orr versus sunitinib lenvima plus everolimus also showed significant improvements pfs orr versus sunitinib merck eisai discuss data regulatory authorities worldwide intent submit marketing authorization applications based results december merck eisai announced pivotal phase keynotestudy trial evaluating investigational use keytruda plus lenvima met dual primary endpoints os pfs secondary efficacy endpoint orr patients advanced endometrial cancer following least one prior platinumbased regimen positive results observed mismatch repair proficient pmmr subgroup itt study population includes patients endometrial carcinoma pmmr well patients whose disease msihdmmr based analysis conducted independent dmc keytruda plus lenvima demonstrated statistically significant clinically meaningful improvement os pfs orr versus chemotherapy merck eisai discuss data regulatory authorities worldwide intent table contents submit marketing authorization applications based results plan present results upcoming medical meeting keynotestudy confirmatory trial keynotestudy supported accelerated approval fda keytruda plus lenvima combination treatment patients advanced endometrial carcinoma msih dmmr disease progression following prior systemic therapy candidates curative surgery radiation merck eisai continuing study keytruda plus lenvima combination leap lenvatinib pembrolizumab clinical program across trials different tumor types endometrial carcinoma hcc melanoma nsclc rcc squamous cell carcinoma head neck urothelial cancer biliary tract cancer colorectal cancer gastric cancer glioblastoma ovarian cancer tnbc mk belzutifan investigational hypoxiainducible factor hif inhibitor evaluated treatment patients von hippel lindau vhl diseaseassociated rcc nonmetastatic rcc tumors less three centimeters size unless immediate surgery required july fda granted breakthrough therapy designation belzutifan also granted orphan drug designation belzutifan vhl disease designations based data phase trial evaluating belzutifan patients vhlassociated ccrcc presented asco annual meeting additionally phase data showing antitumor responses vhl disease patients ccrcc tumors presented esmo virtual congress february merck eisai began phase trial examining lenvima combination belzutifan previously treated patients metastatic rcc mk tukysa small molecule tyrosine kinase inhibitor treatment herpositive cancers september seagen granted merck exclusive license entered codevelopment agreement merck accelerate global reach tukysa merck seagen also announced collaboration globally develop commercialize seagens ladiratuzumab vedotin mk investigational antibodydrug conjugate targeting liv currently phase clinical trials breast cancer solid tumors collaboration pursue broad joint development program evaluating ladiratuzumab vedotin monotherapy combination keytruda tnbc hormone receptorpositive breast cancer livexpressing solid tumors mk lynparza oral parp inhibitor currently approved certain types advanced ovarian breast pancreatic prostate cancers co developed multiple cancer types part collaboration astrazeneca mk gefapixant investigational orally administered selective px receptor antagonist treatment refractory unexplained chronic cough september merck announced results two ongoing pivotal phase trials cough cough evaluating efficacy safety gefapixant studies adult patients treated gefapixant mg twice daily demonstrated statistically significant reduction hour cough frequency versus placebo weeks cough weeks cough gefapixant mg twice daily treatment arms meet primary efficacy endpoint either phase study results presented virtual european respiratory society international congress merck plans share data cough cough regulatory authorities worldwide mk also known cdfc investigational treatment patients hospitalized covid merck obtained mk acquisition oncoimmune september oncoimmune reported topline findings interim efficacy analysis phase study evaluating mk interim analysis data participants planned enrollment indicated selected hospitalized patients covid treated single dose mk showed higher probability improvement clinical status compared placebo defined protocol risk death respiratory failure reduced full results phase study consistent topline results received february submitted publication future mk also studied phase trial treatment graft versus host disease molnupiravir also known mk orally available antiviral candidate treatment covid developed collaboration ridgeback biotherapeutics lp currently evaluated table contents phase clinical trials hospital outpatient settings primary completion date phase studies june company anticipates interim efficacy data first quarter mka combination islatravir companys investigational oral nucleoside reverse transcriptase translocation inhibitor nrtti doravirine pifeltro evaluated treatment hiv infection october merck announced week data phase b trial nct evaluating efficacy safety mka treatmentnave adults hiv infection week findings demonstrated combination islatravir doravirine maintained virologic suppression similar delstrigo doravirinelamivudinetenofovir disoproxil fumarate findings consistent week results additional week data study show low rates participants meeting definition protocoldefined virologic failure islatravir plus doravirine delstrigo treatment arms participants either arm met criteria resistance testing data presented virtual international congress drug therapy hiv infection hiv glasgow november merck announced collaboration bill melinda gates foundation foundation foundation committing provide funding support pivotal phase study investigating oncemonthly oral preexposure prophylaxis prep option women adolescent girls high risk acquiring hiv infection subsaharan africa study impower evaluate efficacy safety oncemonthly islatravir anticipated begin early merck funding impower clinical trial united states merck also plans conduct additional studies hiv prevention islatravir oncemonthly oral prep studies include impower global phase clinical trial evaluate islatravir oncemonthly oral agent prep sites across world among key populations impacted epidemic including men sex men transgender women january fda accepted standard review supplemental nda steglatro ertugliflozin incorporate results phase vertis cardiovascular cv outcomes trial product labeling vertis cv trial evaluated steglatro oral sodiumglucose cotransporter sglt inhibitor versus placebo added background standard care treatment patients type diabetes atherosclerotic cv disease study met primary endpoint noninferiority major adverse cv events mace composite cv death nonfatal myocardial infarction nonfatal stroke compared placebo key secondary endpoints superiority steglatro versus placebo time first occurrence composite cv death hospitalization heart failure time cv death alone time first occurrence composite renal death dialysistransplant doubling serum creatinine baseline met prespecified hypothesis statistical testing reduction hospitalization heart failure observed steglatro supplemental application also submitted ema currently review january company announced discontinuation clinical development programs covid vaccine candidates v v following mercks review findings phase clinical studies vaccines studies v v generally well tolerated immune responses inferior seen following natural infection reported sarscovcovid vaccines chart reflects companys research pipeline february candidates shown phase include specific products date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area respect cancer additional claims line extensions formulations inline products shown table contents phase phase phase entry date review antiviral covid cancer new molecular entitiesvaccines mk molnupiravir mk keytruda bacterial infection cancer biliary tract september mka relebactamimipenemcilastatin jpn mk cervical october eu heart failure hematological malignancies cutaneous squamous cell august eu mk vericiguat eu jpn mk quavonlimab endometrial august eu pediatric neurofibromatosis type melanoma gastric may eu mk selumetinib eu nonsmallcell lung hepatocellular may eu pneumococcal infection adult solid tumors mesothelioma may v us eu mk ovarian december head neck prostate may mk smallcell lung may eu advanced solid tumors mk belzutifan mk keytruda renal cell february certain supplemental filings advanced solid tumors mk tukysa cancer mk breast october mk keytruda hematological malignancies mk lynparza metastatic triplenegative breast cancer nonsmallcell lung colorectal august keynote eu jpn mk nonsmallcell lung june earlystage triplenegative breast cancer nonsmallcell lung smallcell lung december keynote us mk mk lenvima refractory classical hodgkin lymphoma nonsmallcell lung bladder may keynote eu mk ladiratuzumab vedotin endometrial june eu unresectable metastatic msih dmmr colorectal cancer advanced solid tumors gastric december keynote jpn breast head neck february cutaneous squamous cell cancer mk tukysa melanoma march keynote us advanced solid tumors nonsmallcell lung march advanced unresectable metastatic colorectal cough esophageal cancer keynote gastric mk gefapixant march us eu jpn mk lynparza covid firstline metastatic gastric cancer advanced solid tumors mk december keynote us mk vibostolimab hiv infection mk lenvima melanoma mka doravirineislatravir february firstline metastatic hepatocellular carcinoma nonsmallcell lung keynote us mk lenvima thymic carcinoma ncchremora jpn advanced solid tumors biliary tract colorectal glioblastoma footnotes v breast developed collaboration cutaneous squamous cell developed combination keytruda head neck melanoma developed monotherapy combination keytruda solid tumors july fda issued crl mercks eisais applications chikungunya virus merck eisai intend submit additional data available fda v cytomegalovirus v hiv prevention mk islatravir nonalcoholic steatohepatitis nash mk overgrowth syndrome mk miransertib pneumococcal vaccine adult v respiratory syncytial virus mk schizophrenia mk human capital december company approximately employees worldwide approximately employed united states including puerto rico approximately thirdparty contractors globally approximately companys employees full timeemployees women individuals ethnically diverse backgrounds comprise approximately workforce united states respectively women comprise members board directors additionally companys executive team includes individuals two structural levels chief executive table contents officer made women approximately companys employees represented various collective bargaining groups company recognizes employees critical meet needs patients customers ability excel depends integrity skill diversity employees talent acquisition company uses comprehensive approach ensure recruiting retention leadership development goals systematically executed throughout company hires talented leaders achieve improved gender parity representation across dimensions diversity company provides training managers external recruiting organizations strategies mitigate unconscious bias candidate selection hiring process addition company utilizes comprehensive communications strategy marketing outreach social media strategic alliance partnerships reach broad pool talent critical business areas company hired approximately employees across globe various channels including companys external career site diversity partnerships employee referrals universities external sources global diversity inclusion diversity inclusion fundamental companys success core future innovation company fosters globally diverse inclusive workforce employees creating environment belonging engagement equity empowerment company proactive intentional diversity hiring development programs advance talent company creates competitive advantages leveraging diversity inclusion accelerate business performance includes fostering global supplier diversity integrating diversity inclusion companys commercialization strategies leveraging employee insights improve performance addition efforts company ten employee business resource groups provide opportunities employees take active part contributing companys inclusive culture work talent acquisition development business customer insights social community outreach gender ethnicity performance data women workforce women workforce us nr women board directors women executive roles women management roles members underrepresented ethnic groups board directors members underrepresented ethnic groups executive roles us members underrepresented ethnic groups workforce us members underrepresented ethnic groups management roles us new hires female new hires members underrepresented ethnic groups us nr reported executive defined chief executive officer two structural levels management role defined managers direct reports executives defined note compensation benefits company provides valuable total rewards package reflecting commitment attract retain motivate talent supporting employees families every stage life company continuously monitors adjusts compensation benefit programs ensure competitive contemporary helpful engaging support strategic imperatives diversity inclusion equity flexibility quality security affordability example company added personal health care concierge service assist us employees participating company medical plan health care table contents needs aligned business support cancer care strategy company also improved cancer screening benefits added resources provided immediate access leading cancer center excellence us employees globally company implemented minimum standard weeks paid parental leave inclusively applies parents united states companys benefits rank top quartile fortune companies aon hewitt benefits index company included working mother best companies ranking consecutive years named working mother best company dads employee wellbeing company committed helping employees families improve health wellbeing companys culture wellbeing referred live includes programs support preventive health emotional financial wellbeing physical fitness nutrition designed inspire employees pursue enjoy share healthy lifestyles live launched united states today available every country company employees addition many companys larger sites offer onsite health clinics provide array services help employees stay get well including vaccinations cancer biometric screenings travel medicine advice diagnosis treatment nonoccupational illnesses injuries health counseling referrals companys overall employee wellbeing program recognized excellence health wellbeing receiving highest level awards business group health american heart association covid response company recognizes unique responsibility help response covid pandemic committed supporting protecting employees families ensuring supply medicines vaccines reaches patients contributing scientific expertise development antiviral approaches supporting health care providers communities serve company continues provide employees easy regular access information including details regarding companys tracking process guidance around hygiene measures travel best practices working home examples pandemic support resources programs available companys employees include pay continuation workers sick exposed volunteer policy adjustment enable employees medical backgrounds volunteer sarscovrelated activities resources prioritize physical mental wellness adjustments medical plans cover covidrelated diagnosis testing treatment backup childcare engaging employees company strives foster employee engagement promoting safe positive diverse inclusive work environment provides numerous opportunities twoway communication employees companys key programs initiatives include promoting global employee engagement surveys ongoing pulse checks organization interim feedback specific topics fostering professional networking collaboration identifying providing opportunities volunteering establishing positive cooperative business relations designated employee representatives talent management development company pursues goal becoming worlds premier researchbased biopharmaceutical company needs continuously develop diverse talented people companys current talent management system supports companywide performance management development talent reviews succession planning annual performance reviews help professional development companys employees ensure companys workforce aligned companys objectives company seeks continuously build skills capabilities workforce accelerate talent improve performance mitigate risk relevant continuous learning experiences includes limited building leadership management skills well providing technical functional training employees environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures table contents remediation environmental liabilities million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying accruing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures material adverse effect companys financial condition results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy usage water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states percentage total company sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished us securities exchange commission sec address website wwwsecgov addition company provide without charge copy annual report including financial statements schedules upon written request shareholder office secretary merck co inc galloping hill road k kenilworth nj usa companys corporate governance guidelines charters board directors four standing committees available companys website wwwmerckcomcompanyoverviewleadership information available print shareholder requests company item risk factors summary risk factors company subject number risks realized could materially adversely affect business results operations cash flow financial condition prospects following summary principal risk factors facing company company dependent patent rights patent rights invalidated circumvented business could materially adversely affected companys products lose market exclusivity company generally experiences significant rapid loss sales products table contents key products generate significant amount companys profits cash flows events adversely affect markets leading products could material adverse effect companys results operations financial condition companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lose patent protection companys success dependent successful development marketing new products subject substantial risks company faces continued pricing pressure respect products uncertainty global economic conditions together costreduction measures taken certain governments could negatively affect companys operating results company faces intense competition lower cost generic products company faces intense competition competitors products global covid pandemic adverse impact companys business operations financial performance company unable predict full extent covid pandemic future pandemic epidemic similar public health threat adversely impact business operations financial performance results operations financial condition company significant global operations expose additional risks adverse event could material adverse effect companys results operations financial condition failure attract retain highly qualified personnel could affect companys ability successfully develop commercialize products past company experienced difficulties delays manufacturing certain products including vaccines company may able realize expected benefits investments emerging markets company exposed market risk fluctuations currency exchange rates interest rates pharmaceutical products develop unexpected safety efficacy concerns reliance thirdparty relationships outsourcing arrangements could materially adversely affect companys business negative events animal health industry could material adverse effect future results operations financial condition biologics vaccines carry unique risks uncertainties could material adverse effect companys future results operations financial condition health care industry united states continue subject increasing regulation political action companys products including products development marketed unless company obtains maintains regulatory approval developments following regulatory approval may adversely affect sales companys products company subject variety us international laws regulations table contents company subject evolving complex tax laws may result additional liabilities may affect results operations financial condition product liability insurance products may limited cost prohibitive unavailable company increasingly dependent sophisticated software applications computing infrastructure cloud service providers company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations company could target future cyberattacks social media platforms present risks challenges proposed spinoff organon may completed terms timeline currently contemplated may achieve expected results costs complete proposed spinoff significant addition company may unable achieve strategic financial benefits expects achieve spinoff organon following spinoff price shares companys common stock may fluctuate significantly could significant income tax liability spinoff certain related transactions determined taxable us federal income tax purposes list exhaustive company faces additional challenges risks investors carefully consider information set forth including following risk factors deciding invest companys securities risk factors risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations cash flow prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results risks related companys business company dependent patent rights patent rights invalidated circumvented business could materially adversely affected patent protection considered aggregate material importance companys marketing human health animal health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents claims third parties infringement company company defends patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated ndas fda seeking market generic forms companys products prior expiration relevant patents owned licensed company company normally responds defending patent including filing lawsuits alleging patent table contents infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating companies patents potential legislation united states certain foreign markets relating patents well regulatory initiatives may result general weakening intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available companys results operations may adversely affected lost sales unless company launched commercially successful products replace lost sales addition products measured fair value capitalized connection acquisitions experience difficulties market negatively affect product cash flows company may recognize material noncash impairment charges respect value products chart listing patent protection certain companys marketed products us patent protection candidates phase clinical development set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss market exclusivity material adverse effect companys business cash flow results operations financial condition prospects example patent provided us market exclusivity nuvaring expired april generic competition began december company experienced rapid substantial decline us nuvaring sales result generic competition addition januvia janumet lose market exclusivity united states january januvia lose market exclusivity eu september finally spc provides market exclusivity janumet eu expires april company anticipates sales januvia janumet markets decline substantially loss market exclusivity key products generate significant amount companys profits cash flows events adversely affect markets leading products could material adverse effect companys results operations financial condition companys ability generate profits operating cash flow depends largely upon continued profitability companys key products keytruda gardasilgardasil januvia janumet bridion particular companys oncology portfolio led keytruda represented vast majority companys revenue growth result companys dependence key products event adversely affects products markets products could significant adverse impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postapproval trials increased competition introduction new effective treatments discontinuation removal market product reason events could material adverse effect sales products table contents companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lose patent protection order remain competitive company like major pharmaceutical companies must continue launch new products expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop collaborations joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs vaccines result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results competing products manufacturers may reach market first clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved regulators intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial condition prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications anticipated labeling uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others table contents future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection acquisitions certain collaborations failure successfully develop market new products short term long term would material adverse effect companys business results operations cash flow financial condition prospects company faces continued pricing pressure respect products company faces continued pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca iii state activities aimed increasing price transparency including new laws noted item competition health care environment changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition united states larger customers received higher rebates drugs certain highly competitive categories company must also compete placed formularies managed care organizations exclusion product formulary lead reduced usage managed care organization order provide information companys pricing practices company annually posts website pricing transparency report united states report provides companys average annual list price net price increases across companys us portfolio dating back companys gross us sales reduced result rebates discounts returns outside united states numerous major markets including eu japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines furthermore government order repricing specific products determines use product exceed certain thresholds defined applicable repricing rules next governmentmandated price reduction occur april expected impact many company products company expects pricing pressures continue future uncertainty global economic conditions together costreduction measures taken certain governments could negatively affect companys operating results uncertainty global economic geopolitical conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial condition prospects discussed competition health care environment global efforts toward health care cost containment continue exert pressure product pricing market access worldwide changes us health care system part health care reform well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets government mandated pricing actions reduced prices generic patented drugs addition companys revenue performance negatively affected costreduction measures taken governments thirdparties lower health care costs company anticipates actions additional actions future continue negatively affect revenue performance table contents credit economic conditions worsen resulting economic currency impacts affected markets globally could material adverse effect companys results company faces intense competition lower cost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states eu political pressure reduce spending prescription drugs led legislation measures encourage use generic biosimilar products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial condition prospects company faces intense competition competitors products companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective convenient use better insurance coverage reimbursement levels effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial condition prospects addition products measured fair value capitalized connection acquisitions experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products global covid pandemic adverse impact companys business operations financial performance company unable predict full extent covid pandemic future pandemic epidemic similar public health threat adversely impact business operations financial performance results operations financial condition companys business financial results negatively impacted outbreak covid continued duration severity covid pandemic uncertain rapidly changing difficult predict degree covid impacts companys results depend future developments beyond companys knowledge control including limited duration outbreak severity success actions taken contain prevent virus treat impact quickly extent normal economic operating conditions resume covid pandemic impacted companys business numerous ways expected within companys human health business revenue negatively impacted reduced access health care providers given social distancing measures negatively affected vaccine oncology sales particular estimated overall negative impact covid pandemic mercks revenue full year approximately billion largely attributable pharmaceutical segment approximately million attributable animal health segment roughly twothirds mercks pharmaceutical segment revenue comprised physicianadministered products despite strong underlying demand affected social distancing measures fewer well visits delays elective surgeries due covid pandemic impacts well prioritization covid patients health care providers resulted reduced administration many companys human health products particular vaccines including gardasil well keytruda implanon table contents nexplanon addition declines elective surgeries negatively affected demand bridion however sales pneumovax increased due heightened awareness pneumococcal vaccination merck believes global health systems patients largely adapted impacts covid companys assumption ongoing residual negative impacts persist particularly first half notably respect vaccine sales impact expected acute united states full year merck assumes unfavorable impact revenue approximately due covid pandemic relates pharmaceutical segment sales addition full year respect covid pandemic merck expects net negative impact operating expenses spending development covid antiviral programs expected exceed favorable impact lower spending areas due covid pandemic despite companys efforts manage impacts ultimate impact also depend factors beyond companys knowledge control including duration covid virus well governmental thirdparty actions taken contain prevent spread treat virus mitigate public health economic effects addition future pandemic epidemic similar public health threat could present similar risks companys business cash flow results operations financial condition prospects company significant global operations expose additional risks adverse event could material adverse effect companys results operations financial condition extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements including imposition trade sanctions similar restrictions united states governments foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease failure attract retain highly qualified personnel could affect companys ability successfully develop commercialize products companys success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry intense company sure able attract retain quality personnel costs materially increase past company experienced difficulties delays manufacturing certain products including vaccines merck past experienced difficulties manufacturing certain products including vaccines example company issued product recall zerbaxa following identification product sterility issues company may future experience difficulties delays manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead table contents manufacturing shutdowns product shortages delays product manufacturing ii delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply addition company could experience difficulties delays manufacturing products caused natural disasters hurricanes manufacturing difficulties result product shortages leading lost sales reputational harm company company may able realize expected benefits investments emerging markets company taking steps increase sales emerging markets however guarantee companys efforts expand sales markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business outside united states increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys currently marketed products absence trade impediments adverse pricing controls noted competition health care environment pricing pressure china increased chinese government taking steps reduce costs including implementing health care reform led acceleration generic substitution available chinese government updated nrdl first time eight years mechanism drugs added list evolves inclusion may require price negotiation could impact outlook market selected brands drugs added nrdl doubledigit price reductions pricing pressure always existed china health care reform increased pressure part due acceleration generic substitution governments vbp program government implemented vbp program tendering process mature products generic substitutes generic quality consistency evaluation approval mature products entered first three rounds vbp average price reduction company expects vbp semiannual process significant impact mature products moving forward addition company anticipates reported inquiries made various governmental authorities involving multinational pharmaceutical companies china may continue reasons sales within emerging markets carry significant risks however time macroeconomic growth selected emerging markets expected outpace europe even united states leading significant increased headcount spending countries access innovative medicines patients failure maintain companys presence emerging markets could therefore material adverse effect companys business cash flow results operations financial condition prospects company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter business development transactions borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates inflation could negatively affect companys business cash flow results operations financial condition prospects table contents order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options forwards interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful certain companys interest rate derivatives investments based london interbank offered rate libor portion mercks indebtedness bears interest variable interest rates primarily based libor libor subject recent national international regulatory guidance proposals reform cause libor cease exist entirely future company expects reasonable alternatives libor implemented prior termination company predict consequences timing developments could include increase interest expense may also require amendment contracts reference libor pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions reliance thirdparty relationships outsourcing arrangements could materially adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies thirdparty service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business negative events animal health industry could material adverse effect future results operations financial condition future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals african swine fever could lead widespread death precautionary destruction well reduced consumption demand animals could adversely affect companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt manufacture animal health products sites force company incur substantial expenses procuring raw materials products elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant biologics vaccines carry unique risks uncertainties could material adverse effect companys future results operations financial condition successful development testing manufacturing commercialization biologics vaccines particularly human animal health vaccines long complex expensive uncertain process unique risks uncertainties related biologics vaccines including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs table contents development manufacturing marketing biologics vaccines subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval generally required release manufactured commercial lot manufacturing biologics vaccines especially large quantities often complex may require use innovative technologies handle living microorganisms lot approved biologic vaccine must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics vaccines frequently costly manufacture production ingredients derived living animal plant material biologics vaccines made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead variability manufacturing process could lead allegations harm including infections allergic reactions allegations would reviewed standard investigation process could lead closure product facilities due possible contamination events could result substantial costs risks relating government regulation legal proceedings health care industry united states continue subject increasing regulation political action discussed competition health care environment company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered executive branch congress state legislatures united states enacted major health care reform legislation form aca various insurance market reforms advanced state federal insurance exchanges launched aca increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program aca also requires pharmaceutical manufacturers pay cost medicine including biosimilar products medicare part beneficiaries medicare part coverage gap ie socalled donut hole companys revenue reduced approximately million due requirement also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee company recorded million costs annual fee february centers medicare medicaid services cms issued medicaid rebate final rule implemented provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs recently although cms previously declined define constitutes product line extension beyond statutory definition cms issued new rule december significantly expand definition term line extension january include broad range products including products reflecting new strengths dosage forms release mechanisms routes administration expanded definition increase number drugs subject higher medicaid rebate effective january final rule also changes way manufacturers must calculate best price relation certain patient support programs including coupons also may result increase table contents companys medicaid rebates impact provisions final rule could adversely impact companys business cash flow results operations financial condition prospects discussed competition health care environment november department health human services office inspector general oig issued final rule would effective january eliminate antikickback statute safe harbor rebates paid medicare part plans pbms behalf plans company anticipate effects change way currently contracts new framework could significantly alter way business part plan sponsors pbms behalf plans november cms also issued mfn rule intended effective january institute new pricing system certain prescription drugs biologic products covered medicare part b medicare would reimburse favored nation price meaning lowest price adjusting volume differences gross domestic product top fifty part b reimbursed products includes keytruda sold member countries oecd rather use current average sales price aspbased payment framework certain physicianadministered drugs implementation mfn rule could material adverse effect companys business cash flow results operations financial condition prospects fda also recently issued rulemaking allowing commercial importation certain prescription drugs canada fdaauthorized time limited programs sponsored states native american tribes recognized rule certain future circumstances pharmacists wholesalers fda also recently released final guidance industry detailing procedures drug manufacturers import fdaapproved prescription drug biological combination products manufactured abroad authorized intended sale foreign country changes become effective could material adverse effect companys business cash flow results operations financial condition prospects several organizations including two trade groups merck member filed suit challenging mfn rule lawsuits remain pending preliminary injunction entered one cases trade organization merck member brought suit pending federal district court challenging commercial importation rule company predict likelihood regulations becoming effective additional future changes health care industry general pharmaceutical industry particular occur however changes could material adverse effect companys business cash flow results operations financial condition prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including eu japan china united states fda administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases reduction cost drugs fda foreign regulatory authorities including japan china substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling products jurisdiction company would able realize revenues new products jurisdiction approval table contents developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval may decrease demand companys products including following results postapproval phase trials studies rereview products already marketed recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy quality labeling changes scrutiny advertising promotion past clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pmda chinas nmpa increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities addition dissemination promotional materials evolving digital channels serves increase visibility scrutiny marketplace company subject variety us international laws regulations company currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business cash flow results operations financial condition prospects company laws regulations include additional health care reform initiatives united states countries including additional mandatory discounts fees ii us foreign corrupt practices act antibribery corruption laws iii new laws regulations judicial governmental decisions affecting pricing drug reimbursement access marketing within across jurisdictions iv changes intellectual property laws v changes accounting standards vi new increasing data privacy regulations enforcement particularly eu united states vii legislative mandates preferences local manufacturing pharmaceutical vaccine products viii emerging new global regulatory requirements reporting payments value transfers health care professionals ix environmental regulations x potential impact importation restrictions embargoes trade sanctions legislative andor regulatory changes table contents company subject evolving complex tax laws may result additional liabilities may affect results operations financial condition company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition company may negatively affected changes tax laws new tax laws affecting example tax rates andor revised tax law interpretations domestic foreign jurisdictions product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost insurance increased significantly company subject substantial number product liability claims see item financial statements supplementary data note contingencies environmental liabilities information companys current product liability litigation respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise risks related technology company increasingly dependent sophisticated software applications computing infrastructure company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations company could target future cyberattacks company increasingly dependent sophisticated software applications complex information technology systems computing infrastructure cloud service providers collectively systems conduct critical operations certain systems managed hosted provided used third parties assist conducting companys business disruption degradation manipulation systems intentional accidental means companys employees third parties authorized access unauthorized third parties could adversely affect key business processes cyberattacks companys systems thirdparty providers systems cloudbased systems could result exposure confidential information modification critical data andor failure critical operations misuse systems could result disclosure sensitive personal information theft trade secrets intellectual property confidential business information company continues leverage new innovative technologies across enterprise improve efficacy efficiency business processes use create new risks company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations resulting losses company implemented variety measures enhance modernize systems guard similar attacks future also pursuing enterprisewide effort enhance company 's resiliency future cyberattacks including incidents similar attack objective efforts protect future cyberattacks also improve speed companys recovery attacks enable continued business operations greatest extent possible recovery period although aggregate impact cyberattacks network disruptions including cyberattack companys operations financial condition material date company continues target events nature expects continue company monitors data information technology personnel usage company systems reduce risks continues ongoing table contents basis current potential threats assurance companys efforts protect data systems efforts thirdparty providers protect systems successful preventing disruptions companys operations including manufacturing research sales operations disruptions past could future result loss revenue loss critical sensitive information companys companys thirdparty providers databases systems past could future also result financial legal business reputational harm company substantial remediation costs social media platforms present risks challenges inappropriate andor unauthorized use certain social media channels could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments company products social networking platforms could damage companys reputation brand image goodwill disclosure nonpublic companysensitive information companys workforce others external media channels could lead information loss although internal company social media policy guides employees appropriate personal professional use social media company processes place may completely secure protect information identifying new points entry social media continues expand also presents new challenges risks related proposed spinoff organon proposed spinoff organon may completed terms timeline currently contemplated may achieve expected results february company announced intention spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders distribution expected qualify taxfree company shareholders us federal income tax purposes transaction expected completed late second quarter completion spinoff subject number factors conditions assurances company able complete spinoff terms timeline announced unanticipated developments could delay prevent otherwise adversely affect proposed spinoff including limited disruptions general financial market conditions potential problems delays obtaining various regulatory tax approvals clearances addition consummation proposed spinoff require final approval companys board directors costs complete proposed spinoff significant addition company may unable achieve strategic financial benefits expects achieve spinoff organon company incur significant expenses connection spinoff addition company may able achieve full strategic financial benefits expected result spinoff anticipated benefits spinoff based number assumptions may prove incorrect following spinoff price shares companys common stock may fluctuate significantly company predict effect spinoff trading price shares common stock market value shares common stock may less equal greater market value shares common stock prior spinoff addition price mercks common stock may volatile around time spinoff could significant income tax liability spinoff certain related transactions determined taxable us federal income tax purposes company expects prior completion spinoff receive opinion us tax counsel concludes among things spinoff outstanding organon shares merck table contents shareholders certain related transactions qualify taxfree merck shareholders sections us internal revenue code except extent cash received lieu fractional shares organon common stock opinion binding internal revenue service irs accordingly company believes risk low irs may reach conclusions respect spinoff different conclusions reached opinion opinion rely certain facts assumptions representations undertakings merck organon regarding past future conduct companies respective businesses matters incomplete incorrect satisfied could alter conclusions party giving opinion proposed spinoff ultimately determined taxable company believes unlikely spinoff could treated taxable dividend mercks shareholders us federal income tax purposes mercks shareholders could incur significant us federal income tax liabilities addition merck would recognize taxable gain extent fair market value organon common stock exceeds mercks tax basis stock date spinoff cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals product potential development programs include statements related expected impact covid pandemic one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic andor biosimilar products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general impact global covid pandemic future pandemic epidemic similar public health threat companys business operations financial performance changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business table contents efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products cyberattacks companys thirdparty providers information technology systems could disrupt companys operations lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates proposed spinoff might delayed costs complete spinoff might significant expected list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters currently located kenilworth new jersey company previously announced intends consolidate new jersey campuses single corporate headquarters location rahway new jersey end company also maintains operational divisional headquarters kenilworth new jersey madison new jersey upper gwynedd pennsylvania principal us research facilities located rahway kenilworth new jersey west point pennsylvania boston massachusetts south san francisco california elkhorn nebraska animal health principal research facilities outside united states located united kingdom switzerland china mercks manufacturing operations currently headquartered whitehouse station new jersey company also production facilities human health products nine locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties japan singapore south africa countries western europe central south america asia number properties transferred organon spinoff capital expenditures billion billion billion united states amounted billion billion billion abroad expenditures amounted billion billion billion table contents company subsidiaries principal facilities manufacturing plants titles consider satisfactory company believes properties good operating condition machinery equipment well maintained company believes plants manufacture products suitable intended purposes capacities projected capacities including previouslydisclosed capital expansion projects adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable table contents executive officers registrant ages february officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer persons name age offices business experience kenneth c frazier chairman president chief executive officer since december sanat chattopadhyay executive vice president president merck manufacturing division since march frank clyburn executive vice president chief commercial officer since january president global oncology business unit october december robert davis executive vice president global services chief financial officer since april executive vice president chief financial officer april april richard r deluca jr executive vice president president merck animal health since september michael w fleming senior vice president chief ethics compliance officer since march senior vice president international legal compliance january march vice president international legal compliance july january julie l gerberding executive vice president chief patient officer strategic communications global public policy population health since july executive vice president strategic communications global public policy population health january july rita karachun senior vice president finance global controller since march dean li president merck research laboratories since january senior vice president discovery sciences translational medicine merck research laboratories november january vice president translational medicine march november prior chief scientific officer associate vice president university utah health sciences steven c mizell executive vice president chief human resources officer since december executive vice president human resources monsanto company august december michael nally executive vice president chief marketing officer since january president global vaccines global human health september january managing director united kingdom ireland global human health january september jennifer zachary executive vice president general counsel corporate secretary since january executive vice president general counsel april january partner covington burling llp january march february merck announced kenneth c frazier chairman chief executive officer retire chief executive officer effective june mr frazier continue serve mercks board directors executive chairman transition period determined board merck board directors unanimously elected robert davis mercks current executive vice president global services chief financial officer chief executive officer well member board effective july mr davis become president merck effective april time companys operating divisionshuman health animal health manufacturing merck research laboratorieswill begin reporting mr davis table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk january approximately shareholders record companys common stock issuer purchases equity securities three months ended december follows issuer purchases equity securities millions total number average price approximate dollar value shares shares paid per may yet purchased period purchased share plans programs october october november november december december total company purchase shares three months ended december plan approved board directors october purchase billion merck shares treasury table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major us europeanbased pharmaceutical companies abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company glaxosmithkline plc novartis ag pfizer inc roche holding ag sanofi sa comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp compound annual growth rate peer group average calculated market cap weighted basis performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed sec subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act table contents item managements discussion analysis financial condition results operations following section generally discusses results yeartoyear comparisons discussion results yeartoyear comparisons included found managements discussion analysis financial condition results operations part ii item companys annual report fiscal year ended december filed february description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include two operating segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers company previously healthcare services segment provided services solutions focused engagement health analytics clinical services improve value care delivered patients company divested remaining businesses segment first quarter company previously alliances segment primarily included activity companys relationship astrazeneca lp related sales nexium prilosec concluded planned spinoff womens health biosimilars established brands new company february merck announced intention spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders distribution expected qualify taxfree company shareholders us federal income tax purposes established brands included transaction consist dermatology nonopioid pain management respiratory select cardiovascular products including zetia vytorin well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned organon development capabilities initially focused latestage development lifecycle management expected time develop research capabilities selected therapeutic areas spinoff expected completed late second quarter subject market certain conditions table contents overview financial highlights change excluding foreign millions change exchange sales net income attributable merck co inc nongaap net income attributable merck co inc earnings per common share assuming dilution attributable merck co inc common shareholders nongaap earnings per common share assuming dilution attributable merck co inc common shareholders nongaap net income nongaap earnings per share eps exclude acquisition divestiturerelated costs restructuring costs certain items discussion reconciliation gaap nongaap net income eps see nongaap income nongaap eps executive summary worldwide sales billion increase compared excluding unfavorable effect foreign exchange sales increase driven primarily oncology certain hospital acute care products animal health growth areas largely offset negative effects coronavirus disease covid pandemic discussed effects generic competition particularly diversified brands womens health franchises competitive pressure virology franchise pricing pressure diabetes franchise merck continued executing strategic priorities reporting yearoveryear sales growth despite business challenges posed covid pandemic roughly twothirds mercks pharmaceutical segment revenue comprised physicianadministered products sales negatively affected patients inability access health care providers fewer well visits social distancing measures however latter part year company experienced partial recovery underlying demand products across key growth pillars despite pandemic merck employees across organization continued important work enrolling maintaining clinical studies progressing pipeline ensuring supply patient access companys portfolio medically important medicines vaccines company also executed mercks capital allocation priorities completing business development transactions investing pipeline additionally company remains track complete spinoff organon late second quarter thereby creating two companies focused strengths portfolios allowing pursue respective market opportunities business strategies products comprise organon total sales billion merck actively monitors business development landscape growth opportunities meet companys strategic criteria expand oncology presence merck completed acquisitions arqule inc arqule biopharmaceutical company focused kinase inhibitor discovery development treatment cancer diseases velosbio inc velosbio clinicalstage biopharmaceutical company committed developing firstinclass cancer therapies targeting receptor tyrosine kinaselike orphan receptor ror currently evaluated treatment patients hematologic malignancies solid tumors additionally merck entered strategic collaboration agreements seagen gain access ladiratuzumab vedotin investigational antibody drug conjugate targeting liv tukysa tucatinib small molecule tyrosine kinase inhibitor treatment human epidermal growth factor receptor herpositive cancers augment mercks animal health business company acquired us rights sentinel flavor tabs sentinel spectrum chews part industrywide efforts develop solutions pandemic company acquired oncoimmune company developing therapeutic candidate treatment patients hospitalized covid themis bioscience gmbh themis company focused vaccines immunemodulation therapies infectious diseases including covid vaccine candidate additionally merck entered table contents strategic collaborations ridgeback biotherapeutics lp ridgeback bio develop orally available antiviral candidate clinical development treatment patients covid international aids vaccine initiative inc iavi develop investigational vaccine sarscov studied prevention covid january company announced discontinuing development covid vaccine candidates see note consolidated financial statements company received numerous regulatory approvals within oncology keytruda received approval united states monotherapy therapeutic areas cutaneous squamous cell carcinoma cscc metastatic microsatellite instabilityhigh msih mismatch repair deficient dmmr colorectal cancer nonmuscle invasive bladder cancer nmibc tumor mutational burdenhigh tmbh solid tumors well combination chemotherapy treatment triplenegative breast cancer tnbc merck also received approval united states every six weeks qw dosing regimen across adult indications additionally keytruda received approval china treatment certain patients head neck squamous cell carcinoma hnscc china japan treatment certain patients esophageal squamous cell carcinoma escc lynparza developed collaboration astrazeneca plc astrazeneca received approval united states combination bevacizumab firstline maintenance treatment certain adult patients advanced epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbased chemotherapy treatment certain adult patients metastatic castrationresistant prostate cancer mcrpc following progression prior treatment additionally lynparza approved european union eu monotherapy treatment adult patients mcrpc brca mutations progressed following prior therapy maintenance treatment certain adult patients metastatic adenocarcinoma pancreas lynparza also approved japan treatment three types advanced cancer ovarian prostate pancreatic cancer lenvima developed collaboration eisai co ltd eisai received approval china monotherapy treatment differentiated thyroid cancer also gardasil approved use women girls japan marketed silgard additionally us food drug administration fda granted accelerated approval expanded indication gardasil prevention oropharyngeal head neck cancers caused certain hpv types january company received fda approval verquvo vericiguat reduce risk cardiovascular death heart failure hospitalization following hospitalization heart failure need outpatient intravenous diuretics adults verquvo jointly developed bayer ag bayer addition recent regulatory approvals discussed company advanced latestage pipeline several regulatory submissions keytruda review united states andor internationally treatment certain patients tnbc classical hodgkin lymphoma chl colorectal cancer cscc esophageal gastric cancer lenvima review japan monotherapy treatment thymic cancer v investigational valent pneumococcal conjugate vaccine priority review fda prevention invasive pneumococcal disease adults years age older european medicines agency ema also reviewing application licensure v adults company involved litigation challenging validity several pfizer inc patents relate pneumococcal vaccine technology united states several foreign jurisdictions companys phase oncology programs include keytruda therapeutic areas biliary tract cervical cutaneous squamous cell endometrial gastric hepatocellular mesothelioma ovarian prostate smallcell lung cancers lynparza monotherapy colorectal cancer combination keytruda nonsmallcell lung smallcell lung cancers lenvima combination keytruda bladder endometrial gastric head neck melanoma non smallcell lung cancers also within oncology mk belzutifan investigational hypoxiainducible factor alpha hif inhibitor evaluated treatment patients von hippellindau diseaseassociated renal cell carcinoma rcc received breakthrough therapy designation fda additionally company candidates phase clinical development several therapeutic areas including mk gefapixant selective nonnarcotic orally administered investigational pxreceptor antagonist developed treatment refractory chronic cough mk investigational treatment patients hospitalized covid mka islatravir investigational nucleoside reverse transcriptase translocation inhibitor nrtti combination doravirine treatment hiv infection v evaluated prevention pneumococcal disease pediatric patients table contents company allocating resources support commercial opportunities near term making necessary investments support long term growth research development expenses reflect higher costs related business development activity higher clinical development spending increased investment discovery research early drug development november mercks board directors approved increase companys quarterly dividend raising per share per share companys outstanding common stock company returned billion shareholders dividends share repurchases management february merck announced kenneth c frazier chairman chief executive officer retire chief executive officer effective june mr frazier continue serve mercks board directors executive chairman transition period determined board merck board directors unanimously elected robert davis mercks current executive vice president global services chief financial officer chief executive officer well member board effective july mr davis become president merck effective april time companys operating divisionshuman health animal health manufacturing merck research laboratories mrlwill begin reporting mr davis covid overall response covid pandemic merck remains focused protecting safety employees ensuring supply medicines vaccines reaches patients contributing scientific expertise development antiviral approaches supporting health care providers mercks communities although covidrelated disruptions patients ability access health care providers negatively affected results merck remains confident fundamental underlying demand products prospects longterm growth estimated negative impact covid pandemic mercks sales approximately billion largely attributable pharmaceutical segment approximately million attributable animal health segment roughly twothirds mercks pharmaceutical segment revenue comprised physicianadministered products despite strong underlying demand affected social distancing measures fewer well visits delays elective surgeries due covid pandemic impacts well prioritization covid patients health care providers resulted reduced administration many companys human health products particular vaccines including gardasil well keytruda implanonnexplanon addition declines elective surgeries negatively affected demand bridion however sales pneumovax increased due heightened awareness pneumococcal vaccination operating expenses positively affected approximately million primarily due lower promotional selling costs well lower research development expenses net investments covidrelated antiviral vaccine research programs merck believes global health systems patients largely adapted impacts covid companys assumption ongoing residual negative impacts persist particularly first half notably respect vaccine sales impact expected acute united states full year merck assumes unfavorable impact revenue approximately due covid pandemic relates pharmaceutical segment sales addition full year respect covid pandemic merck expects net negative impact operating expenses spending development covid antiviral programs expected exceed favorable impact lower spending areas due covid pandemic pricing global efforts toward health care cost containment continue exert pressure product pricing market access worldwide changes us health care system part health care reform well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys revenue performance negatively table contents affected costreduction measures taken governments thirdparties lower health care costs company anticipates actions additional actions future continue negatively affect revenue performance operating results sales change change excluding foreign excluding foreign millions change exchange change exchange united states international total us plus international may equal total due rounding worldwide sales grew due higher sales oncology franchise reflecting strong growth keytruda well increased alliance revenue lynparza lenvima also contributing revenue growth higher sales certain vaccines including gardasilgardasil pneumovax well increased sales certain hospital acute care products including prevymis bridion higher sales animal health products also drove revenue growth sales growth partially offset effects generic competition certain products including womens health product nuvaring hospital acute care products noxafil cubicin oncology products emendemend injection cardiovascular products zetia vytorin products within diversified brands franchise particularly singulair diversified brands franchise includes certain products approaching expiration marketing exclusivity longer protected patents developed markets lower sales pediatric vaccines including proquad mmr ii varivax well lower sales diabetes products januvia janumet virology products zepatier isentressisentress hd also partially offset revenue growth discussed covid pandemic negatively affected sales sales united states grew primarily driven higher sales keytruda increased alliance revenue lynparza lenvima higher sales animal health products revenue growth largely offset lower sales nuvaring januvia noxafil emendemend injection mmr ii janumet varivax implanonnexplanon international sales grew increase international sales primarily reflects growth keytruda gardasilgardasil increased alliance revenue lynparza well higher sales pneumovax prevymis januvia animal health products sales growth partially offset lower sales zepatier vytorin noxafil zetia remicade emendemend injection products within diversified brands franchise particularly singulair nasonex international sales represented total sales see note consolidated financial statements details sales companys products discussion performance select products franchises follows pharmaceutical segment oncology change excluding change foreign excluding foreign millions change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima emend alliance revenue represents mercks share profits product sales net cost sales commercialization costs see note consolidated financial statements table contents keytruda antipd programmed death receptor therapy approved monotherapy treatment certain patients cervical cancer chl cscc escc gastric gastroesophageal junction adenocarcinoma hnscc hepatocellular carcinoma hcc nonsmallcell lung cancer nsclc smallcell lung cancer sclc melanoma merkel cell carcinoma msih dmmr cancer including msihdmmr colorectal cancer primary mediastinal large bcell lymphoma pmbcl tmbh cancer urothelial carcinoma including nmibc keytruda also approved treatment certain patients combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination chemotherapy tnbc combination axitinib rcc combination lenvima endometrial carcinoma keytruda clinical development program includes studies across broad range cancer types global sales keytruda grew driven higher demand company continues launch keytruda multiple new indications globally although covid pandemic dampening effect growing demand sales united states continue build across multiple approved indications particular treatment advanced nsclc monotherapy combination chemotherapy nonsquamous squamous metastatic nsclc along uptake rcc adjuvant melanoma hnscc bladder cancer endometrial carcinoma indications uptake every six weeks qw adult dosing regimen united states benefited sales keytruda sales growth international markets driven continued uptake approved indications particularly eu sales growth partially offset declines japan due pricing pursuant repricing rule japanese government reduced price keytruda effective february additionally keytruda subject another price reduction april provision japanese pricing rules january fda approved keytruda monotherapy treatment certain patients bacillus calmetteguerin bcgunresponsive highrisk nmibc based results keynote trial april fda granted accelerated approval additional recommended dosage mg every six weeks qw keytruda across adult indications including monotherapy combination therapy new dosage option available addition current dose mg every three weeks qw june fda granted accelerated approval keytruda monotherapy treatment adult pediatric patients unresectable metastatic tmbh solid tumors determined fdaapproved test progressed following prior treatment satisfactory alternative treatment options based part results keynote trial also june fda approved keytruda monotherapy treatment patients recurrent metastatic cscc curable surgery radiation based data keynote trial additionally june fda approved keytruda monotherapy firstline treatment patients unresectable metastatic msih dmmr colorectal cancer based results keynote trial october fda approved expanded label keytruda monotherapy treatment adult patients relapsed refractory chl based results keynote trial fda also approved updated pediatric indication keytruda treatment pediatric patients refractory chl chl relapsed two lines therapy keytruda previously approved fdas accelerated approval process treatment adult pediatric patients refractory chl relapsed three prior lines therapy based data keynote trial accordance accelerated approval regulations continued approval contingent upon verification description clinical benefit accelerated approval requirements fulfilled data keynote november fda granted accelerated approval keytruda combination chemotherapy treatment patients locally recurrent unresectable metastatic tnbc whose tumors express pdl combined positive score cps determined fdaapproved test approval based results keynote trial june keytruda approved national medical products administration nmpa china monotherapy secondline treatment patients locally advanced metastatic escc whose table contents tumors express pdl cps indication granted based keynote trial including data extension global study chinese patients december chinas nmpa approved keytruda monotherapy firstline treatment patients metastatic unresectable recurrent hnscc whose tumors express pdl cps determined fully validated test august keytruda approved japans pharmaceuticals medical devices agency pmda monotherapy treatment patients whose tumors pdlpositive radically unresectable advanced recurrent escc progressed chemotherapy approval based results keynote trial additionally keytruda approved japans pmda use additional recommended dosage mg qw including monotherapy combination therapy new dosage option available addition current dose mg qw january keytruda approved european commission ec firstline treatment adult patients msih dmmr colorectal cancer based results keynote study company party certain thirdparty license agreements pursuant company pays royalties sales keytruda terms significant agreements merck pays royalty worldwide sales keytruda one third party royalty decline terminate thereafter company pays additional royalty worldwide sales keytruda another third party termination date varies country royalty expire united states major european markets royalties included cost sales lynparza oral poly adpribose polymerase parp inhibitor developed part collaboration astrazeneca see note consolidated financial statements approved treatment certain types advanced ovarian breast pancreatic prostate cancers alliance revenue related lynparza grew due continued uptake across multiple approved indications united states eu china japan may fda approved lynparza combination bevacizumab firstline maintenance treatment certain adult patients advanced epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbased chemotherapy november lynparza approved eu maintenance treatment adult patients advanced highgrade epithelial ovarian fallopian tube primary peritoneal cancer complete partial response following completion firstline platinumbased chemotherapy combination bevacizumab whose cancer associated homologous recombination deficiency hrdpositive status approvals based results paola trial also may fda approved lynparza treatment adult patients deleterious suspected deleterious germline somatic homologous recombination repair hrr genemutated mcrpc progressed following prior treatment november lynparza approved eu monotherapy treatment adult patients mcrpc brca mutations germline andor somatic progressed following prior therapy approvals based results profound trial july lynparza approved eu monotherapy maintenance treatment adult patients germline brca mutations metastatic adenocarcinoma pancreas progressed firstline chemotherapy regimen approval based results polo trial december lynparza approved japan treatment three types advanced cancer ovarian prostate pancreatic cancer three approvals authorize lynparza use maintenance treatment firstline chemotherapy containing bevacizumab genetical recombination patients hrd ovarian cancer treatment patients brca genemutated brcam mcrpc maintenance treatment platinumbased chemotherapy patients brcam curatively unresectable pancreas cancer concurrent approvals japanese ministry health labor welfare based results paola profound polo trials lenvima oral receptor tyrosine kinase inhibitor developed part collaboration eisai see note consolidated financial statements approved treatment certain types thyroid cancer hcc combination everolimus certain patients rcc combination keytruda table contents treatment certain patients endometrial carcinoma alliance revenue related lenvima grew due higher demand united states china eu november chinas nmpa approved lenvima monotherapy treatment differentiated thyroid cancer global sales emend prevention certain chemotherapyinduced nausea vomiting declined primarily due lower demand pricing united states due generic competition emend injection following us patent expiry september also contributing emend sales decline lower demand eu japan result generic competition oral formulation emend following loss market exclusivity may december respectively us market exclusivity oral formulation emend previously expired april fda approved koselugo selumetinib treatment pediatric patients two years age older neurofibromatosis type nf symptomatic inoperable plexiform neurofibromas pn fda approval based positive results national cancer institute nci cancer therapy evaluation program ctepsponsored phase sprint stratum trial coordinated ncis center cancer research pediatric oncology branch first regulatory approval medicine treatment nf pn rare debilitating genetic condition koselugo jointly developed commercialized astrazeneca globally see note consolidated financial statements vaccines change excluding change foreign excluding foreign millions change exchange change exchange gardasilgardasil proquad mmr ii varivax pneumovax worldwide sales gardasilgardasil vaccines help prevent certain cancers diseases caused certain types hpv grew primarily due higher volumes china replenishment doses borrowed us centers disease control prevention cdc pediatric vaccine stockpile replenishment resulted recognition sales million combined reduction sales million due borrowing resulted favorable impact sales million lower demand united states hong kong sar prc attributable covid pandemic partially offset increase sales gardasilgardasil june fda approved expanded indication gardasil prevention oropharyngeal head neck cancers caused hpv types oropharyngeal head neck cancer indication approved accelerated approval based effectiveness preventing hpvrelated anogenital disease july gardasil approved pmda japan use women girls nine years older prevention cervical cancer certain cervical vaginal vulvar precancers genital warts caused hpv types covered vaccine december silgard also approved japan prevention anal cancer precursor lesions caused hpv types individuals nine years older genital warts men nine years older gardasil marketed japan silgard company party certain thirdparty license agreements pursuant company pays royalties sales gardasilgardasil terms significant agreements merck pays royalty worldwide sales gardasilgardasil one third party royalty obligations agreement expire december additional royalty sales gardasilgardasil united states another third party royalty obligations expire december royalties included cost sales table contents global sales proquad pediatric combination vaccine help protect measles mumps rubella varicella declined driven primarily lower demand united states resulting fewer measles outbreaks compared coupled unfavorable impact covid pandemic partially offset higher pricing worldwide sales mmr ii vaccine help protect measles mumps rubella declined driven primarily lower demand united states resulting fewer measles outbreaks compared coupled unfavorable impact covid pandemic lower demand brazil also contributed mmr ii sales decline global sales varivax vaccine help prevent chickenpox varicella declined driven primarily lower demand united states resulting covid pandemic partially offset higher pricing varivax sales decline also attributable lower government tenders brazil worldwide sales pneumovax vaccine help prevent pneumococcal disease grew primarily due higher volumes eu united states attributable part heightened awareness pneumococcal vaccination higher pricing united states also contributed pneumovax sales growth hospital acute care change change excluding foreign excluding foreign millions change exchange change exchange bridion noxafil prevymis cubicin zerbaxa global sales bridion reversal two types neuromuscular blocking agents used surgery grew due higher demand globally particularly united states however fewer elective surgeries result covid pandemic unfavorably affected demand worldwide sales noxafil antifungal agent prevention certain invasive fungal infections declined due generic competition united states eu patent provided us market exclusivity certain forms noxafil representing majority us noxafil sales expired july additionally patent noxafil expired number major european markets december result company experiencing volume pricing declines noxafil sales markets result generic competition expects declines continue worldwide sales prevymis medicine prophylaxis prevention cytomegalovirus cmv infection disease adult cmvseropositive recipients allogenic hematopoietic stem cell transplant grew due continued uptake since launch eu united states prevymis approved ec january fda november global sales cubicin injection antibiotic treatment certain bacterial infections declined primarily due ongoing generic competition eu united states december company temporarily suspended sales zerbaxa combination antibacterial betalactamase inhibitor treatment certain bacterial infections subsequently issued product recall following identification product sterility issues result company recorded intangible asset impairment charge related zerbaxa see note consolidated financial statements company anticipate zerbaxa return market june fda approved supplemental new drug application nda recarbrio imipenem cilastatin relebactam treatment patients years age older hospitalacquired table contents bacterial pneumonia ventilatorassociated bacterial pneumonia caused certain susceptible gramnegative microorganisms immunology change change excluding foreign excluding foreign millions change exchange change exchange simponi remicade sales simponi oncemonthly subcutaneous treatment certain inflammatory diseases marketed company europe russia turkey nearly flat sales simponi unfavorably affected launch biosimilars competing product company expects competition continue unfavorably affect sales simponi sales remicade treatment inflammatory diseases marketed company europe russia turkey declined driven ongoing biosimilar competition companys marketing territories europe company lost market exclusivity remicade major european markets longer market exclusivity marketing territories company experiencing pricing volume declines markets result biosimilar competition expects declines continue companys marketing rights respect products revert janssen pharmaceuticals inc second half virology change excluding change foreign excluding foreign millions change exchange change exchange isentressisentress hd zepatier worldwide sales isentressisentress hd hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection declined primarily due competitive pressure united states eu company expects competitive pressures isentressisentress hd continue global sales zepatier treatment adult patients chronic hepatitis c virus genotype gt gt infection declined driven lower demand globally due competition declining patient volumes coupled impact covid pandemic cardiovascular change change excluding foreign excluding foreign millions change exchange change exchange zetiavytorin atozet rosuzet alliance revenue adempas adempas alliance revenue represents mercks share profits sales bayers marketing territories product sales net cost sales commercialization costs see note consolidated financial statements combined global sales zetia marketed countries outside united states ezetrol vytorin marketed outside united states inegy medicines lowering ldl cholesterol declined driven primarily lower sales ezetrol japan ezetrol inegy eu patent provided market exclusivity ezetrol japan expired september generic competition began june table contents eu patents ezetrol inegy expired april april respectively accordingly company experiencing sales declines markets result generic competition expects declines continue sales decline also attributable lower pricing following loss exclusivity australia higher demand ezetrol china partially offset sales decline merck lost market exclusivity united states zetia vytorin subsequently lost nearly us sales products result generic competition sales atozet marketed outside united states medicine lowering ldl cholesterol grew primarily driven higher demand markets particularly eu japan countries asia pacific region zetia vytorin atozet rosuzet contributed organon connection spinoff see note consolidated financial statements adempas cardiovascular drug treatment pulmonary arterial hypertension part worldwide collaboration bayer market develop soluble guanylate cyclase sgc modulators including adempas see note consolidated financial statements revenue adempas includes mercks share profits sale adempas bayers marketing territories grew well sales mercks marketing territories grew january fda approved verquvo vericiguat sgc stimulator reduce risk cardiovascular death heart failure hospitalization following hospitalization heart failure need outpatient intravenous diuretics adults symptomatic chronic heart failure reduced ejection fraction approval based results pivotal phase victoria trial follows priority regulatory review verquvo part worldwide clinical development collaboration bayer includes adempas referenced diabetes change change excluding foreign excluding foreign millions change exchange change exchange januviajanumet worldwide combined sales januvia janumet medicines help lower blood sugar levels adults type diabetes declined result continued pricing pressure united states partially offset higher demand certain international markets particularly china company expects us pricing pressure continue januvia janumet lose market exclusivity united states january supplementary patent certificates provide market exclusivity januvia janumet eu expire september april respectively company anticipates sales januvia janumet markets decline substantially loss market exclusivity womens health change excluding change foreign excluding foreign millions change exchange change exchange implanonnexplanon nuvaring worldwide sales implanonnexplanon singlerod subdermal contraceptive implant declined primarily driven lower demand united states eu resulting covid pandemic worldwide sales nuvaring vaginal contraceptive product declined due generic competition united states patent provided us market exclusivity nuvaring expired april generic competition began december accordingly company experiencing rapid substantial decline us nuvaring sales expects decline continue table contents implanonnexplanon nuvaring contributed organon connection spinoff see note consolidated financial statements biosimilars change change excluding foreign excluding foreign millions change exchange change exchange biosimilars calculation meaningful biosimilar products marketed company pursuant agreement samsung bioepis co ltd samsung develop commercialize multiple prespecified biosimilar candidates currently company markets renflexis infliximababda biosimilar remicade infliximab treatment certain inflammatory diseases ontruzant trastuzumabdttb biosimilar herceptin trastuzumab treatment herpositive breast cancer overexpressing gastric cancer brenzys etanercept biosimilar biosimilar enbrel treatment certain inflammatory diseases aybintio bevacizumab treatment certain types cancer mercks commercialization territories agreement vary product sales growth biosimilars primarily due continued postlaunch uptake renflexis united states canada launch ontruzant brazil august ec granted marketing authorization aybintio treatment metastatic carcinoma colon rectum metastatic breast cancer nsclc advanced andor metastatic rcc epithelial ovarian fallopian tube primary peritoneal cancer cervical cancer application seeking approval aybintio united states filed september biosimilar products contributed organon connection spinoff see note consolidated financial statements animal health segment change change excluding foreign excluding foreign millions change exchange change exchange livestock companion animal sales livestock products grew predominantly due additional five months sales related april acquisition antelliq leader digital animal identification traceability monitoring solutions see note consolidated financial statements sales companion animal products grew driven primarily higher demand bravecto line products parasitic control well higher demand companion animal vaccines costs expenses millions change change cost sales selling general administrative research development restructuring costs income expense net calculation meaningful table contents cost sales cost sales billion compared billion cost sales includes amortization intangible assets recorded connection acquisitions collaborations licensing arrangements totaled billion compared billion respectively additionally costs include intangible asset impairment charges billion million related marketed products intangibles see note consolidated financial statements company may recognize additional impairment charges future related intangible assets measured fair value capitalized connection business acquisitions charges could material costs also include charge million connection discontinuation covid vaccine development programs see note consolidated financial statements inventory writeoffs million related recall zerbaxa see note consolidated financial statements also included cost sales expenses associated restructuring activities amounted million compared million primarily reflecting accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared gross margin decline reflects unfavorable effects higher impairment charges noted pricing pressure charge related discontinuation covid vaccine development programs higher inventory writeoffs related recall zerbaxa noted partially offset favorable effects product mix lower amortization intangible assets lower restructuring costs selling general administrative selling general administrative sga expenses billion decline compared decline driven primarily lower administrative selling promotional costs including lower travel meeting expenses due part covid pandemic favorable effect foreign exchange partially offset higher costs related spinoff organon contribution merck foundation sga expenses include million costs related spinoff organon sga expenses include restructuring costs million million respectively related primarily accelerated depreciation facilities closed divested separation costs associated sales force reductions incurred reflected restructuring costs discussed research development research development rd expenses billion increase compared increase driven primarily higher upfront payments related acquisitions collaborations including billion charge related acquisition velosbio see note consolidated financial statements well higher expenses related clinical development increased investment discovery research early drug development higher restructuring costs also contributed increase rd expenses increase rd expenses partially offset lower inprocess research development iprd impairment charges lower costs resulting covid pandemic net spending covid related vaccine antiviral research programs rd expenses comprised costs directly incurred mrl companys research development division focuses human health related activities billion compared billion also included rd expenses animal health research costs licensing costs costs incurred divisions support rd activities including depreciation production general administrative aggregate billion billion additionally rd expenses include billion charge acquisition velosbio noted million charge acquisition oncoimmune charges million related transactions seagen rd expenses include million charge acquisition peloton see note consolidated financial statements information transactions rd expenses also include iprd impairment charges million million respectively see note consolidated financial statements company may recognize additional impairment charges future related cancellation delay pipeline programs measured fair value capitalized connection business acquisitions table contents charges could material addition rd expenses include million costs associated restructuring activities primarily relating accelerated depreciation rd expenses also include expense income related changes estimated fair value measurement liabilities contingent consideration recorded connection business acquisitions company recorded net reduction expenses million million respectively related changes estimates restructuring costs early merck approved new global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint program continuation companys plant rationalization builds prior restructuring programs include actions associated planned spinoff organon company continues evaluate global footprint overall operating model subsequently identified additional actions restructuring program could identify actions time actions currently contemplated restructuring program expected substantially completed end cumulative pretax costs incurred company implement program estimated approximately billion company expects record charges approximately million related restructuring program company anticipates actions restructuring program result annual net cost savings approximately million end actions previous global restructuring programs substantially completed restructuring costs primarily representing separation related costs associated restructuring activities million million separation costs incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated also included restructuring costs asset abandonment facility shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included cost sales selling general administrative expenses research development costs company recorded aggregate pretax costs million million related restructuring program activities see note consolidated financial statements income expense net income expense net million income compared million expense primarily due higher income investments equity securities net largely related moderna inc details components income expense net see note consolidated financial statements segment profits millions pharmaceutical segment profits animal health segment profits nonreportable segment profits income taxes pharmaceutical segment profits comprised segment sales less standard costs well sga expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well sga rd expenses directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described research development expenses incurred mrl general administrative expenses cost financing activities separate divisions maintain responsibility table contents monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits costs related restructuring activities acquisition divestiturerelated costs including amortization purchase accounting adjustments intangible asset impairment charges changes estimated fair value measurement liabilities contingent consideration additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales pharmaceutical segment profits grew compared driven primarily higher sales well lower selling promotional costs animal health segment profits grew driven primarily higher sales lower promotional selling costs partially offset higher rd costs unfavorable effect foreign exchange taxes income effective income tax rates reflect impacts acquisition divestiturerelated costs restructuring costs partially offset beneficial impact foreign earnings including product mix effective income tax rate reflects unfavorable impact charge acquisition velosbio tax benefit recognized effective income tax rate reflects favorable impact million net tax benefit related settlement certain federal income tax matters see note consolidated financial statements reversal tax reserves established connection divestiture mercks consumer care mcc business due lapse statute limitations addition effective income tax rate reflects unfavorable impacts charge acquisition peloton tax benefit recognized charges million related finalization treasury regulations transition tax associated enactment us tax legislation known tax cuts jobs act tcja see note consolidated financial statements net income loss attributable noncontrolling interests net income loss attributable noncontrolling interests million compared million loss driven primarily portion goodwill impairment charges related certain businesses healthcare services segment attributable noncontrolling interests net income earnings per common share net income attributable merck co inc billion billion eps nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance merck providing management believes information enhances investors understanding companys results permits investors understand management assesses performance nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items considered nonrecurring consist acquisition divestiturerelated costs restructuring costs certain items excluded items significant components understanding assessing financial performance nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap eps management uses measures internally planning forecasting purposes measure performance company along metrics addition senior managements annual compensation derived part using nongaap pretax income since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies information nongaap income nongaap eps considered addition substitute superior net income eps prepared accordance generally accepted accounting principles united states gaap table contents reconciliation gaap financial measures nongaap financial measures follows millions except per share amounts income taxes reported gaap increase decrease excluded items acquisition divestiturerelated costs restructuring costs items charge acquisition velosbio charges formation collaborations charge acquisition oncoimmune charge discontinuation covid vaccine development programs charge acquisition peloton charge related termination collaboration samsung charge acquisition viralytics limited nongaap income taxes taxes income reported gaap estimated tax benefit excluded items adjustment tax benefits recorded conjunction cubist pharmaceuticals inc acquisition net tax benefit settlement certain federal income tax matters tax benefit reversal tax reserves related divestiture mcc net tax charge related finalization treasury regulations related enactment tcja nongaap taxes income nongaap net income less net income loss attributable noncontrolling interests reported gaap acquisition divestiturerelated costs attributable noncontrolling interests nongaap net income attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution reported gaap eps difference nongaap eps assuming dilution amount includes billion intangible asset impairment charge related zerbaxa amount includes million intangible asset impairment charge related sivextro see note consolidated financial statements amount includes million related transactions seagen see note consolidated financial statements amount represents charge formation collaboration eisai see note consolidated financial statements estimated tax impact excluded items determined applying statutory rate originating territory nongaap adjustments acquisition divestiturerelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection business acquisitions divestitures amounts include amortization intangible assets amortization purchase accounting adjustments inventories well intangible asset impairment charges expense income related changes estimated fair value measurement liabilities contingent consideration also excluded integration transaction certain costs associated business acquisitions divestitures restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation table contents associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions restructuring costs also include asset abandonment facility shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans share based compensation costs certain items items adjusted evaluating individual basis considering quantitative qualitative aspects typically consist items unusual nature significant results particular period indicative future operating results excluded nongaap income nongaap eps charges acquisitions velosbio oncoimmune charges related collaborations including transactions seagen see note consolidated financial statements charge discontinuation covid vaccine development programs adjustment tax benefits recorded conjunction cubist pharmaceuticals inc acquisition excluded nongaap income nongaap eps charge acquisition peloton see note consolidated financial statements tax charges related finalization us treasury regulations related tcja net tax benefit related settlement certain federal income tax matters tax benefit related reversal tax reserves established connection divestiture mcc see note consolidated financial statements excluded nongaap income nongaap eps charge related formation collaboration eisai see note consolidated financial statements charge related termination collaboration agreement samsung insulin glargine see note consolidated financial statements charge acquisition viralytics see note consolidated financial statements measurementperiod adjustments related provisional amounts recorded tcja see note consolidated financial statements beginning company changing treatment certain items purposes nongaap reporting historically mercks non gaap results excluded amortization intangible assets recognized connection business acquisitions reflected part acquisition divestiture related costs exclude amortization intangibles originating collaborations asset acquisitions licensing arrangements beginning mercks nongaap results longer differentiate nature intangible assets amortized exclude amortization intangible assets also beginning mercks nongaap results exclude gains losses investments equity securities prior period amounts recast conform new presentation research development research pipeline company currently several candidates regulatory review united states internationally well latestage clinical development chart reflecting companys current research pipeline february related discussion set forth item business research development acquired inprocess research development connection business acquisitions company recorded fair value inprocess research projects time acquisition yet reached technological feasibility december balance iprd billion see note consolidated financial statements iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd table contents acquisition date circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material company recorded iprd impairment charges within research development expenses million million million respectively see note consolidated financial statements additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval acquisitions research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth certain recent transactions summarized additional details included note consolidated financial statements merck actively monitoring landscape growth opportunities meet companys strategic criteria january merck acquired arqule publicly traded biopharmaceutical company focused kinase inhibitor discovery development treatment patients cancer diseases billion arqules lead investigational candidate mk formerly arq novel oral brutons tyrosine kinase btk inhibitor currently evaluated treatment bcell malignancies transaction accounted acquisition business company recorded iprd billion related mk goodwill million net liabilities million july merck ridgeback bio closely held biotechnology company closed collaboration agreement develop molnupiravir mk also known eidd orally available antiviral candidate clinical development treatment patients covid merck gained exclusive worldwide rights develop commercialize molnupiravir related molecules terms agreement ridgeback bio received upfront payment also eligible receive future contingent payments dependent upon achievement certain developmental regulatory approval milestones well share net profits molnupiravir related molecules approved molnupiravir currently evaluated phase clinical trials hospital outpatient settings primary completion date phase studies june company anticipates interim efficacy data first quarter september merck seagen announced oncology collaboration globally develop commercialize seagens ladiratuzumab vedotin mk investigational antibodydrug conjugate targeting liv currently phase clinical trials breast cancer solid tumors terms agreement merck made upfront payment million billion equity investment million shares seagen common stock price per share merck recorded million research development expenses related transaction seagen also eligible receive future contingent milestone payments dependent upon achievement certain developmental salesbased milestones concurrent transaction seagen granted merck exclusive license commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor treatment herpositive cancers asia middle east latin america regions outside united states canada europe terms agreement merck made upfront payments aggregating million recorded research development expenses seagen also eligible receive future contingent regulatory approval milestones tiered royalties based annual sales levels tukysa mercks territories december merck acquired oncoimmune privately held clinicalstage biopharmaceutical company upfront payment million addition oncoimmune shareholders eligible receive future contingent regulatory approval milestone payments tiered royalties oncoimmunes lead therapeutic candidate mk also known cdfc evaluated treatment patients hospitalized covid topline results pre planned interim efficacy analysis phase study mk released september full results phase study consistent topline results received february submitted publication future transaction accounted table contents acquisition asset agreement prior completion acquisition oncoimmune spunout certain rights assets unrelated mk program new entity owned existing shareholders oncoimmune connection closing acquisition merck invested million ownership interest new entity valued million resulting million premium merck also recognized net liabilities million company recorded research development expenses million related transaction december merck announced entered agreement us government support development manufacture initial distribution mk upon approval emergency use authorization eua fda june agreement merck receive approximately million manufacturing supply approximately doses mk us government june help meet governments pandemic response goals following execution agreement merck received feedback fda additional data beyond study conducted oncoimmune would needed support potential eua application based fda feedback merck longer expects supply us government mk first half merck actively working fda address agencys comments december merck acquired velosbio privately held clinicalstage biopharmaceutical company billion velosbios lead investigational candidate mk formerly known vls antibodydrug conjugate targeting receptor tyrosine kinaselike orphan receptor ror currently evaluated treatment patients hematologic malignancies solid tumors transaction accounted acquisition asset merck recorded net assets million primarily cash research development expenses billion related transaction february merck pandion therapeutics inc pandion entered definitive agreement merck acquire pandion clinical stage biotechnology company developing novel therapeutics designed address unmet needs patients living autoimmune diseases per share cash representing approximate total equity value billion pandion advancing pipeline precision immune modulators targeting critical immune control nodes terms acquisition agreement merck subsidiary initiate tender offer acquire outstanding shares pandion closing tender offer subject certain conditions including tender shares representing least majority total number pandions shares fully diluted common stock expiration waiting period hartscottrodino antitrust improvements act customary conditions transaction expected close first half capital expenditures capital expenditures billion billion billion expenditures united states billion billion billion increased capital expenditures reflect investment new capital projects focused primarily increasing manufacturing capacity mercks key products increased capital expenditures also reflect purchase manufacturing facility dunboyne ireland support upcoming product launches see note consolidated financial statements company plans invest billion new capital projects depreciation expense billion billion billion billion billion billion related locations united states total depreciation expense included accelerated depreciation million million respectively associated restructuring activities see note consolidated financial statements table contents analysis liquidity capital resources mercks strong financial profile enables fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt decline working capital compared primarily related increased shortterm debt supporting funding business development activities capital expenditures cash provided operating activities billion compared billion reflecting higher payments related collaborations billion compared million cash provided operating activities continues companys primary source funds finance operating needs capital expenditures treasury stock purchases dividends paid shareholders cash used investing activities billion compared billion increase driven primarily lower proceeds sales securities investments higher use cash acquisitions higher capital expenditures partially offset lower purchases securities investments cash used financing activities billion compared billion lower use cash financing activities driven primarily net increase shortterm borrowings compared net decrease shortterm borrowing well lower purchases treasury stock partially offset higher payments debt see lower proceeds issuance debt see higher dividends paid shareholders lower proceeds exercise stock options company accounts receivable factoring agreements financial institutions certain countries sell accounts receivable see note consolidated financial statements company factored billion billion accounts receivable fourth quarter respectively factoring arrangements reduced outstanding accounts receivable cash received financial institutions reported within operating activities consolidated statement cash flows certain factoring arrangements ease administration company collect customer payments related factored receivables remits financial institutions december company collected million million respectively behalf financial institutions remitted january respectively net cash flows collections reported financing activities consolidated statement cash flows table contents companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations unrecognized tax benefits transition tax related enactment tcja milestone payments related collaborations leases includes future inventory purchases company committed connection certain divestitures december companys consolidated balance sheet reflects liabilities unrecognized tax benefits including interest penalties billion including million reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made connection enactment tcja company required pay onetime transition tax company elected pay period eight years permitted tcja see note consolidated financial statements reflects payments collaborative agreements salesbased milestones achieved therefore deemed contractual obligations paid see note consolidated financial statements amounts exclude reasonably certain lease renewals yet executed see note consolidated financial statements purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising amounts include contingent milestone payments related collaborative arrangements acquisitions considered contractual obligations successful achievement developmental regulatory approval commercial milestones december company recognized liabilities contingent salesbased milestone payments related collaborations astrazeneca eisai payment remains subject achievement related sales milestone aggregating billion see note consolidated financial statements excluded research development obligations potential future funding commitments approximately million investments research venture capital funds loans payable current portion longterm debt reflects million longdated notes subject repayment option holders required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million us pension plans million international pension plans million postretirement benefit plans june company issued billion principal amount senior unsecured notes consisting billion notes due billion notes due billion notes due billion notes due merck used net proceeds offering general corporate purposes including without limitation repayment outstanding commercial paper borrowings indebtedness upcoming maturities march company issued billion principal amount senior unsecured notes consisting million notes due billion notes due billion notes due billion notes due company used net proceeds offering general corporate purposes including repayment outstanding commercial paper borrowings company billion credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility table contents march company filed securities registration statement us securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november mercks board directors declared quarterly dividend per share companys outstanding common stock paid january january board directors declared quarterly dividend per share companys common stock second quarter payable april october mercks board directors authorized purchases billion mercks common stock treasury treasury stock purchase authorization time limit made time openmarket transactions block transactions exchange privately negotiated transactions company spent billion purchase million shares common stock treasury program march company temporarily suspended share repurchase program december companys remaining share repurchase authorization billion company purchased billion billion common stock respectively authorized share repurchase programs company entered accelerated share repurchase asr agreements two thirdparty financial institutions dealers asr agreements merck agreed purchase billion mercks common stock total initial delivery million shares mercks common stock based thencurrent market price made dealers merck payments billion made merck dealers funded existing cash investments well shortterm borrowings upon settlement asr agreements merck received additional million shares determined average daily volume weightedaverage price mercks common stock term asr program less negotiated discount bringing total shares received merck program million financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused changes foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years table contents future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings comprehensive income loss oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges unrealized gains losses contracts recorded accumulated comprehensive income loss aoci reclassified sales hedged anticipated revenue recognized derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes merck principally sells foreign currency revenue hedging program uniform weakening us dollar would yield largest overall potential loss market value hedge instruments market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income taxes would declined approximately million million respectively company net short payable position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows economy argentina determined hyperinflationary consequently accordance us gaap company began remeasuring monetary assets liabilities operations earnings impact companys results immaterial company also uses forward exchange contracts hedge portion net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation unrealized gains losses contracts recorded foreign currency translation adjustment within oci remain aoci either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative table contents instruments assessment hedge effectiveness excluded components changes fair value excluded components recognized oci company recognizes earnings initial value excluded components straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table millions number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due interest rate swaps matured january interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense along offsetting fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting estimates companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including table contents produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements acquisitions dispositions determine whether transactions accounted acquisitions disposals assets businesses company makes certain judgments include assessment inputs processes outputs associated acquired set activities company determines substantially fair value gross assets included transaction concentrated single asset group similar assets assets would represent business considered business assets transaction need include input substantive process together significantly contribute ability create outputs business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition fair values intangible assets including acquired iprd determined utilizing information available near acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probability weighted cash flows subsequent acquisition date reporting period contingency resolved contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize table contents products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd also determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate company determines transaction accounted acquisition business transaction accounted asset acquisition rather business combination therefore goodwill recorded asset acquisition acquired iprd alternative future use charged expense contingent consideration recognized acquisition date instances product development milestones recognized upon achievement salesbased milestones recognized milestone deemed probable company achieved revenue recognition recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts united states sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year us provision aggregate customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases intermediary wholesaler contracted customer generally purchases product wholesaler contracted price plus markup wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly table contents basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued company continually monitors provision aggregate customer discounts material adjustments estimates associated aggregate customer discount provision summarized information changes aggregate customer discount accrual related us sales follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december outside united states variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales outside united states returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically days receipt invoice us animal health customers typically days receipt invoice however certain products including keytruda longer payment terms days outside united states payment terms typically days days although certain markets longer payment terms distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide abovementioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns table contents inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million million respectively contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying accruing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually table contents company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weightedaverage period years segment reporting sharebased compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension plans totaled million million million net periodic benefit credit postretirement benefit plans million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets changes net periodic benefit cost year year pension plans largely attributable changes discount rate affecting net loss amortization company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due discount rates companys us pension postretirement benefit plans ranged december compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data current market conditions actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard table contents deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact companys net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact mercks net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts primarily reflect differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aoci expected returns pension plans based calculated marketrelated value assets net loss amounts aoci excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring programs designed streamline companys cost structure result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing termination costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within cost sales selling general administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill table contents acquired intangible assets excluding iprd initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd company acquires conjunction acquisition business represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects company evaluates iprd impairment least annually frequently impairment indicators exist performing quantitative test compares fair value iprd intangible asset carrying value impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized operating results judgments made evaluating impairment longlived intangibles materially affect companys results operations impairments investments company reviews investments marketable debt securities impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments marketable debt securities including duration extent fair value less cost changes fair value considered temporary reported net tax oci otherthantemporary impairment occurred company expect recover entire amortized cost basis marketable debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci investments publicly traded equity securities reported fair value determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data changes fair value included income expense net investments equity securities without readily determinable fair values recorded cost plus minus subsequent observable price changes orderly transactions identical similar investments minus impairments adjustments recognized income expense net realized gains losses equity securities included income expense net taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement table contents financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements recently issued accounting standards discussion recently issued accounting standards see note consolidated financial statements cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals product potential development programs include statements related expected impact covid pandemic one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses cost sales selling general administrative research development restructuring costs income expense net income taxes taxes income net income less net income loss attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive loss net taxes net unrealized loss gain derivatives net reclassifications net unrealized loss gain investments net reclassifications benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc adoption new accounting standards comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net loss attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net loss attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities amortization depreciation intangible asset impairment charges charge acquisition velosbio inc charge acquisition peloton therapeutics inc charge future payments related collaboration license options deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchase seagen inc common stock purchases securities investments proceeds sales securities investments acquisition velosbio inc net cash acquired acquisition arqule inc net cash acquired acquisition antelliq corporation net cash acquired acquisition peloton therapeutics inc net cash acquired acquisitions net cash acquired net cash used provided investing activities cash flows financing activities net change shortterm borrowings payments debt proceeds issuance debt purchases treasury stock dividends paid stockholders proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents restricted cash net decrease increase cash cash equivalents restricted cash cash cash equivalents restricted cash beginning year includes restricted cash january included assets see note cash cash equivalents restricted cash end year includes restricted cash december included assets see note accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include two operating segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers company previously healthcare services segment provided services solutions focused engagement health analytics clinical services improve value care delivered patients company divested remaining businesses segment first quarter company previously alliances segment primarily included activity companys relationship astrazeneca lp related sales nexium prilosec concluded planned spinoff womens health biosimilars established brands new company february merck announced intention spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders distribution expected qualify taxfree company shareholders us federal income tax purposes established brands included transaction consist dermatology nonopioid pain management respiratory select cardiovascular products including zetia vytorin well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned organon development capabilities initially focused latestage development lifecycle management expected time develop research capabilities selected therapeutic areas spinoff expected completed late second quarter subject market certain conditions subsequent spinoff historical results womens health biosimilars established brands businesses reflected discontinued operations companys consolidated financial statements summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates table contents company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded asset acquisition acquired inprocess research development iprd alternative future use charged expense contingent consideration recognized acquisition date foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost net realizable value cost substantial majority us pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products well certain inventories produced preparation product launches considered high probability regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt securities classified availableforsale reported fair value fair values companys investments marketable debt securities determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax comprehensive income oci company considers available evidence evaluating potential impairments investments marketable debt securities including duration extent fair value less cost thantemporary impairment occurred company expect recover entire amortized cost basis marketable debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related table contents factors recognized oci realized gains losses debt securities included income expense net investments publicly traded equity securities reported fair value determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data changes fair value included income expense net investments equity securities without readily determinable fair values recorded cost plus minus subsequent observable price changes orderly transactions identical similar investments minus impairments adjustments recognized income expense net realized gains losses equity securities included income expense net revenue recognition recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allows companies recognize revenue sales vaccines us government stockpiles even though sales might meet criteria revenue recognition accounting guidance certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts united states sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year us provision aggregate customer discounts covering chargebacks rebates billion billion billion chargebacks discounts occur contracted customer purchases intermediary wholesaler contracted customer generally purchases product wholesaler contracted price plus markup wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities table contents million billion respectively december million billion respectively december outside united states variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch overthecounter products among others outside united states returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically days receipt invoice us animal health customers typically days receipt invoice however certain products including keytruda longer payment terms days outside united states payment terms typically days days although certain markets longer payment terms see note disaggregated revenue disclosures depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development costs included property plant equipment addition company capitalizes certain costs incurred implement cloud computing arrangement considered service agreement included assets capitalized software costs amortized periods ranging years longer lives generally associated enterprisewide projects implemented multiple years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangibles acquired intangibles include products product rights licenses trade names patents initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may recoverable circumstances determined exist estimate undiscounted table contents future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows acquired inprocess research development iprd company acquires conjunction acquisition business represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company evaluates iprd impairment least annually frequently impairment indicators exist performing quantitative test compares fair value iprd intangible asset carrying value fair value less carrying amount impairment loss recognized operating results contingent consideration certain companys acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales transaction accounted acquisition business fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingency resolved contingent consideration liability remeasured current fair value changes either expense income recorded earnings significant events increase decrease probability achieving development regulatory milestones increase decrease projected cash flows result corresponding increases decreases fair values related contingent consideration obligations transaction accounted acquisition asset rather business contingent consideration recognized acquisition date instances product development milestones recognized upon achievement salesbased milestones recognized milestone deemed probable company achieved research development research development expensed incurred nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration research development expenses also include upfront milestone payments related asset acquisitions licensing transactions involving clinical development programs yet received regulatory approval collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners merck principal sales transactions third parties company recognizes sales cost sales selling general administrative expenses gross basis profit sharing amounts pays collaborative partners recorded within cost sales collaborative partner principal sales transactions third parties company records profit sharing amounts received collaborative partners alliance revenue within sales alliance revenue recorded net cost sales includes adjustment share commercialization costs partners accordance collaboration agreement adjustment determined comparing commercialization costs merck incurred directly reported within selling general administrative expenses costs collaborative partner incurred research development costs merck incurs related collaborations recorded within research development expenses cost reimbursements collaborative partner payments received collaborative partner share costs pursuant terms collaboration agreements recorded increases decreases research development expenses table contents addition terms collaboration agreements may require company make payments based upon achievement certain developmental regulatory approval commercial milestones upfront milestone payments payable merck collaborative partners prior regulatory approval expensed incurred included research development expenses payments due collaborative partners upon subsequent regulatory approval capitalized amortized estimated useful life corresponding intangible asset cost sales provided future cash flows support amounts capitalized salesbased milestones payable merck collaborative partners accrued capitalized subject cumulative amortization catchup probable achieved amortization catchup calculated either time first regulatory approval indications unapproved time collaboration formed time formation collaboration approved products related intangible asset recognized amortized cost sales remaining useful life subject impairment testing sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income company accounts tax effects tax global intangible lowtaxed income gilti certain foreign subsidiaries income tax provision period tax arises use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation table contents recently adopted accounting standards june financial accounting standards board fasb issued new guidance accounting credit losses financial instruments new guidance introduces expected loss model estimating credit losses replacing incurred loss model new guidance also changes impairment model availableforsale debt securities requiring use allowance record estimated credit losses subsequent recoveries company adopted new guidance effective january impact companys consolidated financial statements upon adoption november fasb issued new guidance collaborative arrangements intended reduce diversity practice clarifying whether certain transactions collaborative arrangement participants accounted revenue recognition guidance asc company retrospectively adopted new guidance effective january resulted minor changes presentation information related companys collaborative arrangements see note note december fasb issued amended guidance accounting reporting income taxes guidance intended simplify accounting income taxes removing exceptions related certain intraperiod tax allocations deferred tax liabilities clarifying guidance primarily related evaluating stepup tax basis goodwill business combination reflecting enacted changes tax laws rates annual effective tax rate company adopted new guidance effective january impact companys consolidated financial statements upon adoption january fasb issued new guidance intended clarify certain interactions accounting standards related equity securities equity method investments certain derivatives guidance addresses accounting transition equity method accounting measuring certain purchased options forward contracts acquire investments company adopted new guidance effective january impact companys consolidated financial statements upon adoption recently issued accounting standard yet adopted march fasb issued optional guidance ease potential burden accounting recognizing effects reference rate reform financial reporting subsequently issued clarifying amendments guidance provides optional expedients exceptions applying gaap contracts hedging relationships transactions reference london interbank offered rate libor another reference rate expected discontinued reference rate reform optional guidance effective upon issuance applied prospective basis time january december company currently evaluating impact adoption consolidated financial statements acquisitions divestitures research collaborations license agreements company continues pursue acquisitions establishment external alliances research collaborations licensing agreements complement internal research capabilities arrangements often include upfront payments well expense reimbursements payments third party milestone royalty profit share arrangements contingent upon occurrence certain future events linked success asset development company also reviews marketed products pipeline examine candidates may provide value outlicensing part portfolio assessment process may also divest certain assets pro forma financial information acquired businesses presented historical financial results acquired entity significant compared companys financial results transactions december merck acquired oncoimmune privately held clinicalstage biopharmaceutical company upfront payment million addition oncoimmune shareholders eligible receive million future contingent regulatory approval milestone payments tiered royalties ranging oncoimmunes lead therapeutic candidate mk also known cdfc evaluated treatment patients hospitalized coronavirus disease covid transaction accounted acquisition asset agreement prior completion acquisition oncoimmune spunout certain rights assets unrelated mk program new entity owned existing shareholders oncoimmune connection closing acquisition merck invested million ownership interest new entity valued million resulting million premium merck also table contents recognized net liabilities million company recorded research development expenses million related transaction also december merck acquired velosbio inc velosbio privately held clinicalstage biopharmaceutical company billion velosbios lead investigational candidate mk formerly known vls antibodydrug conjugate targeting receptor tyrosine kinaselike orphan receptor ror currently evaluated treatment patients hematologic malignancies solid tumors transaction accounted acquisition asset merck recorded net assets million primarily cash research development expenses billion related transaction september merck seagen inc seagen formerly known seattle genetics inc announced oncology collaboration globally develop commercialize seagens ladiratuzumab vedotin mk investigational antibodydrug conjugate targeting liv currently phase clinical trials breast cancer solid tumors collaboration pursue broad joint development program evaluating ladiratuzumab vedotin monotherapy combination keytruda pembrolizumab triplenegative breast cancer hormone receptorpositive breast cancer livexpressing solid tumors companies equally share profits worldwide terms agreement merck made upfront payment million billion equity investment million shares seagen common stock price per share merck recorded million research development expenses related transaction reflecting upfront payment well million premium relating equity shares based price seagen common stock closing date seagen also eligible receive future contingent milestone payments billion including million development milestones billion salesbased milestones concurrent transaction seagen granted merck exclusive license commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor treatment herpositive cancers asia middle east latin america regions outside united states canada europe merck responsible marketing applications seeking approval territories supported positive results herclimb clinical trial merck also cofund portion tukysa global development plan encompasses several ongoing planned trials across herpositive cancers including breast colorectal gastric cancers set forth global product development plan merck solely fund conduct countryspecific clinical trials necessary support anticipated regulatory applications territories terms agreement merck made upfront payments aggregating million recorded research development expenses seagen also eligible receive future contingent regulatory approval milestones million receive tiered royalties ranging based annual sales levels tukysa mercks territories additionally september merck acquired biologics manufacturing facility located dunboyne ireland takeda pharmaceutical company limited million million transaction accounted acquisition asset merck recorded property plant equipment million net assets million future contingent payments associated acquisition july merck acquired us rights sentinel flavor tabs sentinel spectrum chews virbac corporation million sentinel products provide protection common parasites dogs transaction accounted acquisition asset merck recognized intangible assets million related currently marketed products inventory million acquisition date estimated fair values identifiable intangible assets related currently marketed products determined using income approach actual cash flows likely different assumed intangible assets related currently marketed products amortized estimated useful lives years future contingent payments associated acquisition also july merck ridgeback biotherapeutics lp ridgeback bio closely held biotechnology company closed collaboration agreement develop molnupiravir mk also known eidd orally available antiviral candidate clinical development treatment patients covid merck gained exclusive worldwide rights develop commercialize molnupiravir related molecules terms agreement ridgeback bio received upfront payment also eligible receive future contingent payments dependent upon achievement certain developmental regulatory approval milestones well share net profits molnupiravir related molecules approved merck table contents ridgeback committed ensure medicines developed sarscov causative agent covid accessible affordable globally june merck acquired privately held themis bioscience gmbh themis company focused vaccines including covid vaccine candidate v immunemodulation therapies infectious diseases cancer million acquisition originally provided merck make additional contingent payments million transaction accounted acquisition business company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream using appropriate discount rate dependent nature timing milestone payments merck recognized intangible assets iprd million cash million deferred tax assets million net liabilities million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach actual cash flows likely different assumed january company announced discontinuing development v discussed result company recorded iprd impairment charge million within research development expenses company also recorded reduction research development expenses resulting decrease related liability contingent consideration million since future contingent milestone payments reduced million aggregate including million development milestones million regulatory approval milestones million commercial milestones may merck international aids vaccine initiative inc iavi nonprofit scientific research organization dedicated addressing urgent unmet global health challenges announced collaboration develop v investigational vaccine sarscov studied prevention covid agreement provided upfront payment merck million also provided future contingent payments based sales merck also signed agreement biomedical advanced research development authority barda part office assistant secretary preparedness response within agency united states department health human services provide initial funding support merck effort january company announced discontinuing development v discussed january company announced discontinuation development programs covid vaccine candidates v v following mercks review findings phase clinical studies vaccines studies v v generally well tolerated immune responses inferior seen following natural infection reported sarscovcovid vaccines due discontinuation company recorded charge million million reflected cost sales related fixedasset materials writeoffs well recognition liabilities purchase commitments remaining million costs reflected research development expenses represent amounts related themis acquisition noted iprd impairment charge partially offset reduction related liability contingent consideration january merck acquired arqule inc arqule publicly traded biopharmaceutical company focused kinase inhibitor discovery development treatment patients cancer diseases total consideration paid billion included million sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf arqule company incurred million transaction costs directly related acquisition arqule consisting almost entirely sharebased compensation payments settle nonvested equity awards attributable postcombination service costs included selling general administrative expenses arqules lead investigational candidate mk formerly known arq novel oral brutons tyrosine kinase btk inhibitor currently evaluated treatment bcell malignancies transaction accounted acquisition business table contents estimated fair value assets acquired liabilities assumed arqule follows millions january cash cash equivalents iprd mk formerly arq licensing arrangement arq deferred income tax liabilities assets liabilities net total identifiable net assets goodwill consideration transferred estimated fair value identifiable intangible asset related iprd determined using income approach future net cash flows discounted present value utilizing discount rate actual cash flows likely different assumed goodwill allocated pharmaceutical segment deductible tax purposes transactions july merck acquired peloton therapeutics inc peloton clinicalstage biopharmaceutical company focused development novel small molecule therapeutic candidates targeting hypoxiainducible factor hif treatment patients cancer nononcology diseases pelotons lead candidate mk formerly known pt novel investigational oral hif inhibitor latestage development renal cell carcinoma merck made upfront payment billion additionally former peloton shareholders eligible receive million upon us regulatory approval million upon first commercial sale united states billion salesbased milestones transaction accounted acquisition asset merck recorded cash million deferred tax liabilities million net liabilities million acquisition date well research development expenses million related transaction april merck acquired antelliq corporation antelliq leader digital animal identification traceability monitoring solutions solutions help veterinarians farmers pet owners gather critical data improve management health wellbeing livestock pets merck paid billion acquire outstanding shares antelliq spent billion repay antelliqs debt transaction accounted acquisition business estimated fair value assets acquired liabilities assumed antelliq follows millions april cash cash equivalents accounts receivable inventories property plant equipment identifiable intangible assets useful lives ranging years deferred income tax liabilities assets liabilities net total identifiable net assets goodwill consideration transferred estimated fair values identifiable intangible assets relate primarily trade names determined using income approach future net cash flows discounted present value utilizing discount rate actual cash flows likely different assumed goodwill recognized largely attributable anticipated synergies expected arise acquisition allocated animal health segment goodwill deductible tax purposes table contents companys results include eight months activity antelliq companys results include months activity company incurred million transaction costs directly related acquisition antelliq consisting largely advisory fees reflected selling general administrative expenses also april merck acquired immune design latestage immunotherapy company employing nextgeneration vivo approaches enable bodys immune system fight disease million cash transaction accounted acquisition business merck recognized intangible assets million cash million net assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach actual cash flows likely different assumed transactions company recorded aggregate charge million within cost sales conjunction termination collaboration agreement entered samsung bioepis co ltd samsung insulin glargine charge reflects termination payment million represents reimbursement fees previously paid samsung merck agreement plus interest well release mercks ongoing obligations agreement charge also included fixed asset abandonment charges million inventory writeoffs million well related costs million termination agreement impact companys collaboration samsung june merck acquired viralytics limited viralytics australian publicly traded company focused oncolytic immunotherapy treatments range cancers aud million million transaction provided merck full rights v formerly known cva investigational oncolytic immunotherapy transaction accounted acquisition asset merck recorded net assets million primarily cash acquisition date research development expenses million related transaction future contingent payments associated acquisition march merck eisai co ltd eisai entered strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discovered eisai see note remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company marketing rights products throughout europe russia turkey remicade lost market exclusivity major european markets company longer market exclusivity marketing territories company continues market exclusivity simponi marketing territories profits derived mercks distribution two products countries equally divided merck jj companys marketing rights respect products revert janssen pharmaceuticals inc second half collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners parties arrangements active participants exposed significant risks rewards dependent commercial success activities collaboration mercks significant collaborative arrangements discussed astrazeneca july merck astrazeneca plc astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer types lynparza oral poly adpribose polymerase parp inhibitor currently approved certain types table contents advanced ovarian breast pancreatic prostate cancers companies jointly developing commercializing lynparza monotherapy combination trials potential medicines independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicines keytruda imfinzi companies also jointly developing commercializing astrazenecas koselugo selumetinib oral selective inhibitor mek part mitogenactivated protein kinase mapk pathway multiple indications april koselugo approved us food drug administration fda treatment pediatric patients two years age older neurofibromatosis type symptomatic inoperable plexiform neurofibromas terms agreement astrazeneca merck share development commercialization costs lynparza koselugo monotherapy nonpdlpd combination therapy opportunities profits lynparza koselugo product sales generated monotherapies combination therapies shared equally merck fund development commercialization costs keytruda combination lynparza koselugo astrazeneca fund development commercialization costs imfinzi combination lynparza koselugo astrazeneca principal lynparza koselugo sales transactions merck records share lynparza koselugo product sales net cost sales commercialization costs alliance revenue share development costs associated collaboration part research development expenses reimbursements received astrazeneca research development expenses recognized reductions research development costs part agreement merck made upfront payment astrazeneca billion made payments million multiyear period certain license options million paid december million paid december million paid december upfront payment license option payments reflected research development expenses addition agreement provides additional contingent payments merck astrazeneca related successful achievement salesbased regulatory milestones merck determined probable sales lynparza future would trigger million salesbased milestone payments merck astrazeneca accordingly merck recorded million liabilities corresponding increases intangible asset related lynparza prior merck accrued salesbased milestone payments aggregating billion related lynparza million million million paid astrazeneca respectively potential future salesbased milestone payments billion yet accrued deemed company probable time lynparza received regulatory approvals triggering capitalized milestone payments million million million respectively aggregate merck astrazeneca potential future regulatory milestone payments billion remain agreement intangible asset balance related lynparza includes capitalized salesbased regulatory milestone payments billion december included intangibles net amount amortized estimated useful life supported projected future cash flows subject impairment testing table contents summarized financial information related collaboration follows years ended december alliance revenue lynparza alliance revenue koselugo total alliance revenue cost sales selling general administrative research development december receivables astrazeneca included current assets payables astrazeneca included accrued current liabilities represents amortization capitalized milestone payments includes accrued milestone payments eisai march merck eisai co ltd eisai announced strategic collaboration worldwide codevelopment cocommercialization lenvima lenvatinib orally available tyrosine kinase inhibitor discovered eisai lenvima currently approved treatment certain types thyroid cancer hepatocellular carcinoma combination everolimus certain patients renal cell carcinoma combination keytruda treatment certain patients endometrial carcinoma agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda eisai records lenvima product sales globally eisai principal lenvima sales transactions merck eisai share applicable profits equally merck records share lenvima product sales net cost sales commercialization costs alliance revenue expenses incurred co development shared two companies accordance collaboration agreement reflected research development expenses certain expenses incurred solely merck eisai shareable collaboration agreement including costs incurred excess agreed upon caps costs related certain combination studies keytruda lenvima agreement merck made upfront payment eisai million agreed make payments million certain option rights million paid march million paid march million expected paid march company recorded aggregate charge billion research development expenses related upfront payment future option payments addition agreement provides additional contingent payments merck eisai related successful achievement salesbased regulatory milestones merck determined probable sales lenvima future would trigger salesbased milestone payments aggregating million merck eisai accordingly merck recorded liabilities million corresponding increases intangible asset related lenvima prior merck accrued salesbased milestone payments aggregating million related lenvima million million paid eisai respectively potential future salesbased milestone payments billion yet accrued deemed company probable time lenvima received regulatory approvals triggering capitalized milestone payments million million respectively merck eisai potential future regulatory milestone payments million remain agreement intangible asset balance related lenvima includes capitalized salesbased regulatory milestone payments billion december included intangibles net amount amortized estimated useful life supported projected future cash flows subject impairment testing table contents summarized financial information related collaboration follows years ended december alliance revenue lenvima cost sales selling general administrative research development december receivables eisai included current assets payables eisai included accrued current liabilities payables eisai included noncurrent liabilities represents amortization capitalized milestone payments amount includes billion related upfront payment option payments includes accrued milestone future option payments includes accrued milestone payments bayer ag company entered worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators including bayers adempas riociguat approved treat pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension two companies implemented joint development commercialization strategy collaboration also includes clinical development bayers verquvo vericiguat approved fda january reduce risk cardiovascular death heart failure hospitalization following hospitalization heart failure need outpatient intravenous diuretics adults verquvo review regulatory authorities territories including eu japan agreement bayer commercializes adempas americas merck commercializes rest world verquvo merck commercialize united states bayer commercialize rest world companies share development costs profits sales merck records sales adempas record sales verquvo marketing territories well alliance revenue alliance revenue represents mercks share profits sales bayers marketing territories product sales net cost sales commercialization costs addition agreement provides contingent payments merck bayer related successful achievement salesbased milestones prior merck accrued million salesbased milestone payments collaboration million million paid bayer respectively following fda approval verquvo noted merck determined probable sales adempas verquvo future would trigger remaining million salesbased milestone payment accordingly merck record liability million corresponding increase intangible assets related collaboration first quarter intangible asset balance related collaboration includes acquired intangible asset balance well capitalized salesbased milestone payments million december included intangibles net amount amortized estimated useful life supported projected future cash flows subject impairment testing table contents summarized financial information related collaboration follows years ended december alliance revenue adempas net sales adempas recorded merck total sales cost sales selling general administrative research development december receivables bayer included current assets payables bayer included noncurrent liabilities includes amortization intangible assets represents accrued milestone payment restructuring early merck approved new global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint program continuation companys plant rationalization builds prior restructuring programs include actions associated planned spinoff organon company continues evaluate global footprint overall operating model subsequently identified additional actions restructuring program could identify actions time actions currently contemplated restructuring program expected substantially completed end cumulative pretax costs incurred company implement program estimated approximately billion company estimates approximately cumulative pretax costs result cash outlays primarily related employee separation expense facility shutdown costs approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company expects record charges approximately million related restructuring program actions previous global restructuring programs substantially completed company recorded total pretax costs million million million related restructuring program activities since inception restructuring program december merck recorded total pretax accumulated costs approximately billion segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring program activities type cost separation accelerated costs depreciation total year ended december cost sales selling general administrative research development restructuring costs year ended december cost sales selling general administrative research development restructuring costs year ended december cost sales selling general administrative research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck recording accelerated depreciation revised useful life site assets anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors activity includes asset abandonment facility shutdown related costs well pretax gains losses resulting sales facilities related assets additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note sharebased compensation following table summarizes charges spending relating restructuring program activities separation accelerated costs depreciation total restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december remaining cash outlays expected substantially completed end table contents financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused changes foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year table contents company also uses forward exchange contracts hedge portion net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation unrealized gains losses contracts recorded foreign currency translation adjustment within oci remain aoci either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded components changes fair value excluded components recognized oci company recognizes earnings initial value excluded components straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci effects companys net investment hedges oci consolidated statement income shown amount pretax gain loss recognized amount pretax gain loss recognized income expense net amounts excluded comprehensive income effectiveness testing years ended december net investment hedging relationships foreign exchange contracts eurodenominated notes amounts reclassified aoci income related sale subsidiary interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk february five interest rate swaps notional amounts million matured swaps effectively converted companys billion fixedrate notes due variable rate debt december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due interest rate swaps matured january interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense along offsetting fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows table contents table presents location amounts recorded consolidated balance sheet related cumulative basis adjustments fair value hedges december cumulative amount fair value hedging adjustment increase decrease included carrying amount hedged liabilities carrying amount balance sheet line item hedged item included loans payable current portion longterm debt longterm debt presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative us dollar derivative us dollar balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments interest rate swap contracts current assets interest rate swap contracts assets interest rate swap contracts accrued current liabilities foreign exchange contracts current assets foreign exchange contracts assets foreign exchange contracts accrued current liabilities foreign exchange contracts noncurrent liabilities derivatives designated hedging instruments foreign exchange contracts current assets foreign exchange contracts accrued current liabilities noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amounts subject offset master netting arrangements offset consolidated balance sheet cash collateral postedreceived net amounts table contents table provides information regarding location amount pretax gains losses derivatives designated fair value cash flow hedging relationships sales income expense net comprehensive income loss years ended december financial statement line items effects fair value cash flow hedges recorded gain loss fair value hedging relationships interest rate swap contracts hedged items derivatives designated hedging instruments impact cash flow hedging relationships foreign exchange contracts amount loss gain recognized oci derivatives decrease increase sales result aoci reclassifications interest rate contracts amount gain recognized income expense net derivatives amount loss recognized oci derivatives interest expense component income expense net table provides information regarding income statement effects derivatives designated hedging instruments amount derivative pretax gain loss recognized income years ended december derivatives designated hedging instruments income statement caption foreign exchange contracts income expense net foreign exchange contracts sales interest rate contracts income expense net forward contract related seagen common stock research development expenses derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates derivative contracts serve economic hedges forecasted transactions derivatives serve economic hedges rising treasury rates december company estimates million pretax net unrealized losses derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information investments debt equity securities december follows gross unrealized gross unrealized amortized fair amortized fair cost gains losses value cost gains losses value us government agency securities foreign government bonds commercial paper corporate notes bonds assetbacked securities total debt securities publicly traded equity securities total debt publicly traded equity securities unrealized net gains recognized income expense net equity securities still held december million unrealized net gains recognized income expense net equity securities still held december million december company also million million respectively equity investments without readily determinable fair values included assets company recognized unrealized gains million million respectively income expense net certain equity investments based favorable observable price changes transactions involving similar investments investee addition company recognized unrealized losses million million respectively income expense net related certain investments based unfavorable observable price changes cumulative unrealized gains cumulative unrealized losses based observable prices changes investments equity investments without readily determinable fair values million million respectively fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets liabilities whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well assets liabilities determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using level level level total level level level total assets investments foreign government bonds commercial paper corporate notes bonds assetbacked securities us government agency securities publicly traded equity securities assets us government agency securities publicly traded equity securities derivative assets forward exchange contracts interest rate swaps purchased currency options total assets liabilities liabilities contingent consideration derivative liabilities forward exchange contracts written currency options interest rate swaps total liabilities investments included assets restricted use including payment benefits employee benefit plans fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant december cash cash equivalents include billion billion respectively cash equivalents would considered level fair value hierarchy table contents contingent consideration summarized information changes liabilities contingent consideration associated business acquisitions follows fair value january additions changes estimated fair value payments fair value december recorded cost sales research development expenses income expense net includes cumulative translation adjustments balance december includes million recorded current liability amounts expected paid within next months december million million respectively liabilities relate termination sanofi pasteur msd joint venture part termination merck recorded liability contingent future royalty payments net sales merck products previously sold joint venture december fair value liability determined utilizing estimated amount timing projected cash flows riskadjusted discount rate present value cash flows additions contingent consideration relate acquisition themis changes estimated fair value liabilities contingent consideration largely attributable increases liabilities recorded connection termination sanofi pasteur msd spmsd joint venture increase partially offset decline related discontinuation covid vaccine program obtained acquisition themis payments contingent consideration years relate spmsd liabilities described fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines majority companys accounts receivable arise product sales united states europe china primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor global economic conditions including volatility associated international sovereign economies associated impacts financial markets business companys customers largest accounts receivable balances mckesson corporation amerisourcebergen corporation cardinal health inc represented aggregate approximately total accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales company accounts receivable factoring agreements financial institutions certain countries sell accounts receivable company factored billion billion accounts receivable fourth quarter respectively factoring arrangements reduced outstanding accounts receivable cash received financial institutions reported within operating activities table contents consolidated statement cash flows certain factoring arrangements ease administration company collect customer payments related factored receivables remits financial institutions december company collected million million respectively behalf financial institutions reflected restricted cash current assets related obligation remit cash within accrued current liabilities company remitted cash financial institutions january respectively net cash flows relating collections reported financing activities consolidated statement cash flows cost factoring accounts receivable de minimis derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty cash collateral advanced company counterparties million december cash collateral received company various counterparties million december obligation return collateral recorded accrued current liabilities inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost decrease lifo cost recognized inventories assets inventories valued lifo method comprised approximately billion billion december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million million december respectively inventories produced preparation product launches goodwill intangibles following table summarizes goodwill activity segment pharmaceutical animal health total balance january acquisitions impairments balance december acquisitions divestitures balance december includes cumulative translation adjustments goodwill balances certain adjustments accumulated goodwill impairment losses million december table contents additions goodwill pharmaceutical segment primarily related acquisitions arqule themis see note additions goodwill within animal health segment primarily relate acquisition antelliq see note impairments goodwill within nonreportable segments relate certain businesses within healthcare services segment healthcare services segment fully divested first quarter intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights licenses iprd trade names acquired intangibles include products product rights licenses trade names patents initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives companys significant acquired intangibles net basis related human health marketed products included products product rights december include zerbaxa million implanonnexplanon million gardasilgardasil million dificid million bridion million sivextro million simponi million additionally company billion net acquired intangibles related animal health marketed products december billion relate primarily trade names obtained acquisition antelliq see note companys significant net intangible assets included licenses december include lynparza billion lenvima billion result collaborations astrazeneca eisai see note december iprd primarily relates mk obtained acquisition arqule see note mk gefapixant obtained acquisition afferent pharmaceuticals company intangible asset related collaboration bayer see note carrying value million december reflected table company recorded impairment charge billion within cost sales related zerbaxa injection combination antibacterial betalactamase inhibitor treatment certain bacterial infections december company temporarily suspended sales zerbaxa subsequently issued product recall following identification product sterility issues recall constituted triggering event requiring evaluation zerbaxa intangible asset impairment company revised cash flow forecasts zerbaxa utilizing certain assumptions around return market timeline anticipated uptake sales thereafter revised cash flow forecasts indicated zerbaxa intangible asset value fully recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related zerbaxa compared related carrying value resulted impairment charge noted company also wroteoff inventory million cost sales related zerbaxa recall remaining intangible asset balance related zerbaxa million december company recorded impairment charges related marketed products intangibles million amount million related sivextro product treatment acute bacterial skin skin structure infections caused designated susceptible grampositive organisms part reorganization reprioritization internal sales force company made decision cease promotion sivextro us market end decision resulted reduced cash flow projections sivextro indicated sivextro intangible asset value fully recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related sivextro compared related carrying value resulted impairment charge noted table contents iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized iprd accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life asset begin amortization company recorded million iprd impairment charge within research development expenses related decision discontinue development program covid vaccine candidate v following mercks review findings phase clinical study vaccine study v generally well tolerated immune responses inferior seen following natural infection reported sarscovcovid vaccines discontinuation development program also resulted reversal related liability contingent consideration million see note company recorded million iprd impairment charges amount million relates writeoff intangible asset balance programs obtained connection acquisition iomet pharma ltd following review clinical trial results conducted merck along external clinical trial results similar compounds discontinuation clinical development program also resulted reversal related liability contingent consideration million company recorded million iprd impairment charges amount million relates writeoff remaining intangible asset balance program obtained connection smartcells acquisition following decision terminate program due product development issues discontinuation clinical development program also resulted reversal related liability contingent consideration million iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense primarily recorded within cost sales billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion loans payable longterm debt leases loans payable loans payable december included billion notes due billion commercial paper million longdated notes subject repayment option holders loans payable december included billion notes due billion commercial paper million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings years ended december respectively table contents longterm debt longterm debt december consisted notes due notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due debentures due notes due debentures due debentures due notes due eurodenominated notes due presented table includes million million december respectively borrowings variable rates resulted effective interest rates respectively exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices june company issued billion principal amount senior unsecured notes consisting billion notes due billion notes due billion notes due billion notes due merck used net proceeds offering general corporate purposes including without limitation repayment outstanding commercial paper borrowings indebtedness upcoming maturities effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date certain companys borrowings require merck comply covenants december company compliance covenants table contents aggregate maturities longterm debt next five years follows billion billion billion billion billion company billion credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility leases company operating leases primarily manufacturing facilities research development facilities corporate offices employee housing vehicles certain equipment company determines arrangement lease inception evaluating contracts embedded leases company exercises judgment determine explicit implicit identified asset contract merck controls use asset embedded leases primarily associated contract manufacturing organizations immaterial lease term includes options extend terminate lease reasonably certain merck exercise option real estate leases facilities average remaining lease term eight years include options extend leases four years applicable vehicle leases generally effect four years company record shortterm leases leases initial term months less balance sheet however merck currently shortterm leases lease expense operating lease payments recognized straightline basis term lease operating lease assets liabilities recognized based present value lease payments lease term since companys leases readily determinable implicit discount rate company uses incremental borrowing rate calculate present value lease payments asset class quarterly basis updated incremental borrowing rate determined based average remaining lease term asset class companys pretax cost debt term updated rates asset class applied prospectively new leases company separate lease components eg payments rent real estate taxes insurance costs nonlease components eg commonarea maintenance costs event agreement contains merck includes lease nonlease components purposes calculating rightofuse asset related lease liability nonlease components fixed vehicle leases employee housing company applies portfolio approach effectively account operating lease assets liabilities certain companys lease agreements contain variable lease payments adjusted periodically inflation actual operating expense true ups compared estimated amounts however amounts immaterial sublease income activity related sale leaseback transactions immaterial mercks lease agreements contain material residual value guarantees material restrictive covenants operating lease cost million million rental expense operating leases net sublease income million cash paid amounts included measurement operating lease liabilities million million operating lease assets obtained exchange lease obligations million million supplemental balance sheet information related operating leases follows december assets assets liabilities accrued current liabilities noncurrent liabilities weightedaverage remaining lease term years weightedaverage discount rate includes prepaid leases related lease liability table contents maturities operating leases liabilities follows thereafter total lease payments less imputed interest december company entered additional real estate operating leases yet commenced obligations associated leases total million contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters opinion company unlikely resolution matters material companys financial condition results operations cash flows given nature litigation discussed complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities product liability litigation fosamax previously disclosed merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases pending merck either federal state court plaintiffs vast majority cases generally allege sustained femur fractures andor bone injuries femur fractures association use fosamax federal cases involving allegations femur fractures transferred multidistrict litigation district new jersey femur fracture mdl bellwether case tried date femur fracture mdl glynn v merck jury returned verdict mercks favor addition june femur fracture mdl court granted mercks motion judgment matter law glynn case held plaintiffs failure warn claim preempted federal law table contents august femur fracture mdl court entered order requiring plaintiffs femur fracture mdl show cause cases asserting claims femur fracture injury took place prior september dismissed based courts preemption decision glynn case pursuant show cause order march femur fracture mdl court dismissed prejudice approximately cases preemption grounds plaintiffs approximately cases appealed decision us court appeals third circuit third circuit march third circuit issued decision reversing femur fracture mdl courts preemption ruling remanding appealed cases back femur fracture mdl court may us supreme court decided third circuit incorrectly concluded issue preemption resolved jury accordingly vacated judgment third circuit remanded proceedings back third circuit address issue manner consistent supreme courts opinion november third circuit remanded cases back district court order allow court determine first instance whether plaintiffs state law claims preempted federal law standards described supreme court opinion briefing issue closed parties await decision district court accordingly december approximately cases actively pending femur fracture mdl december approximately cases alleging femur fractures filed new jersey state court pending judge james hyland middlesex county parties selected initial group cases reviewed fact discovery merck continued select additional cases reviewed december approximately cases alleging femur fractures filed pending california state court femur fracture cases filed california state court coordinated single judge orange county california additionally four femur fracture cases pending state courts discovery presently stayed femur fracture mdl state court california merck intends defend lawsuits januviajanumet previously disclosed merck defendant product liability lawsuits united states involving januvia andor janumet december merck aware approximately product users alleging januvia andor janumet caused development pancreatic cancer injuries claims filed multidistrict litigation us district court southern district california mdl outside mdl majority claims filed coordinated proceedings superior court california county los angeles california state court november mdl california state court separate opinions granted summary judgment defendants grounds federal preemption plaintiffs appealed forums november us court appeals ninth circuit vacated judgment remanded discovery november california state appellate court reversed remanded similar grounds march parties mdl california coordinated proceedings agreed coordinate adopt schedule completing discovery general causation preemption issues renewing summary judgment expert motions briefing motions complete hearings mdl california state court judges took place october december respectively december six product users claims pending merck state courts california including illinois june illinois trial court denied mercks motion summary judgment based federal preemption merck appealed illinois appellate court affirmed december merck filed petition leave appeal illinois supreme court february april illinois supreme court stayed consideration pending petition appeal us supreme court issued opinion merck sharp dohme corp v albrecht relating fosamax matter discussed merck filed table contents opinion albrecht illinois supreme court june petition leave appeal decided september illinois supreme court directed intermediate appellate court reconsider earlier ruling illinois appellate court issued favorable decision concluding consistent albrecht preemption presents legal question resolved court may illinois appellate court issued mandate state trial court december scheduled case management conference addition claims noted company agreed toll statute limitations approximately additional claims company intends continue defending lawsuits vioxx merck reached settlement attorney general utah fully resolve states previously disclosed civil lawsuit alleging merck misrepresented safety vioxx part resolution merck paid state million settlement constitute admission merck liability wrongdoing agreement marks final resolution litigation involving vioxx united states ongoing vioxx litigation certain countries outside united states governmental proceedings previously disclosed fall company received records subpoena us attorneys office district vermont vt usao pursuant section health insurance portability accountability act hipaa relating investigation potential health care offenses subpoena sought information relating actual potential business relationship arrangement merck practice fusion inc pfi cloudbased electronic health records ehr company acquired allscripts january company cooperated government responded subpoena subsequently may merck received second records subpoena vt usao broadened governments information request seeking information relating mercks relationship ehr company shortly thereafter vt usao served civil investigation demand cid upon merck similarly seeking information companys relationships ehr vendors cid explains government conducting false claims act investigation concerning whether merck andor pfi submitted claims federal health care programs violate federal antikickback statute merck cooperating governments investigation previously disclosed april merck received set investigative interrogatories california attorney generals office pursuant investigation conduct agreements allegedly affected delayed competition lantus insulin market interrogatories seek information concerning mercks development insulin glargine product subsequent termination well mercks patent litigation sanofi sa concerning lantus resolution litigation merck cooperating california attorney generals investigation previously disclosed june merck received cid us department justice cid requests answers interrogatories well various documents regarding temperature excursions thirdparty storage facility containing certain merck products merck cooperating governments investigation intends produce information andor documents necessary response cid previously disclosed companys subsidiaries china received may continue receive inquiries regarding operations various chinese governmental agencies inquiries may related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate previously disclosed time time company receives inquiries subject preliminary investigation activities competition governmental authorities markets outside united states authorities may include regulators administrative authorities law enforcement similar officials preliminary investigation activities may include site visits formal informal requests demands documents materials inquiries interviews similar matters certain preliminary inquiries activities may lead commencement formal proceedings proceedings determined adversely company monetary fines andor remedial undertakings may required table contents commercial litigation zetia antitrust litigation previously disclosed merck msd schering corporation msp singapore company llc collectively merck defendants defendants putative class action optout lawsuits filed behalf direct indirect purchasers zetia alleging violations federal state antitrust laws well state statutory common law causes action cases consolidated pretrial purposes federal multidistrict litigation judge rebecca beach smith eastern district virginia december court denied merck defendants motions dismiss stay direct purchaser putative class actions pending bilateral arbitration august district court adopted full report recommendation magistrate judge respect merck defendants motions dismiss nonarbitration issues thereby granting part denying part merck defendants motions dismiss addition june representatives putative direct purchaser class filed amended complaint august retailer optout plaintiffs filed amended complaint december district court granted merck defendants motion dismiss extent motion sought dismissal claims overcharges paid entities purchased generic ezetimibe par pharmaceutical inc par pharmaceutical dismissed claims overcharges november direct purchaser plaintiffs indirect purchaser plaintiffs filed motions class certification august district court granted part direct purchasers motion class certification certified class direct purchasers november us court appeals fourth circuit granted merck defendants motion permission appeal district courts order also august magistrate judge recommended court grant motion class certification filed putative indirect purchaser class merck defendants objected report recommendation awaiting decision district court august merck defendants filed motion summary judgment motions plaintiffs filed motion partial summary judgment motions motions fully briefed court likely hold hearing competing motions trial matter adjourned september united healthcare services inc filed lawsuit united states district court district minnesota merck others uhc action uhc action makes similar allegations made zetia class action september united states judicial panel multidistrict litigation transferred case eastern district virginia proceed multidistrict zetia litigation already progress december humana inc filed lawsuit superior court state california county san francisco merck others alleging defendants violated state antitrust laws multiple states also december centene corporation others filed lawsuit superior court state california county san francisco defendants humana lawsuits allege similar anticompetitive acts alleged zetia class action rotavirus vaccines antitrust litigation previously disclosed msd defendant putative class action lawsuits filed behalf direct purchasers rotateq alleging violations federal antitrust laws cases consolidated eastern district pennsylvania january court denied msds motions compel arbitration dismiss consolidated complaint february msd appealed courts order arbitration third circuit october third circuit vacated district courts order remanded limited discovery issue arbitrability july msd filed renewed motion compel arbitration plaintiffs filed cross motion summary judgment arbitrability november district court denied msds motion granted plaintiffs motion december msd filed notice appeal third circuit bravecto litigation previously disclosed january company served complaint united states district court district new jersey seeking certify nationwide class action purchasers users bravecto fluralaner products united states territories may december complaint contends bravecto causes neurological events alleges violations new jersey consumer table contents fraud act breach warranty product liability related theories similar case filed quebec canada may qui tam litigation previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition previously disclosed two putative class action lawsuits behalf direct purchasers mmr ii vaccine charge company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer protection laws pending eastern district pennsylvania september court denied mercks motion dismiss false claims act suit granted part denied part motion dismiss thenpending antitrust suit result false claims act suit antitrust suits proceeded discovery complete parties filed briefed cross motions summary judgment currently pending court company continues defend lawsuits merck kgaa litigation previously disclosed january protect longestablished brand rights united states company filed lawsuit merck kgaa darmstadt germany kgaa historically operating emd group united states alleging improperly uses name merck united states kgaa filed suit company france uk germany switzerland mexico india australia singapore hong kong china alleging among things unfair competition trademark infringement andor corporate name infringement uk australia singapore hong kong india kgaa also alleges breach parties coexistence agreement litigation ongoing united states trial date set also ongoing numerous jurisdictions outside united states company defending suits jurisdiction patent litigation time time generic manufacturers pharmaceutical products file abbreviated new drug applications ndas fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect products acquired acquisitions potentially significant intangible asset impairment charges bridion january november company received multiple paragraph iv certification letters hatchwaxman act notifying company generic drug companies filed applications fda seeking prepatent expiry approval sell generic versions bridion sugammadex injection march april december company filed patent infringement lawsuits us district courts district new jersey northern district west virginia generic companies actions district new jersey consolidated lawsuits assert one patents covering sugammadex methods using sugammadex automatically stay fda approval generic applications june adverse court decisions whichever may occur earlier mylan pharmaceuticals inc mylan api us llc mylan inc mylan filed motions dismiss district new jersey lack venue failure state claim certain defendants northern district west virginia failure state claim certain defendants new jersey motion yet decided west virginia action stayed pending resolution new jersey motion table contents januvia janumet janumet xr fda granted pediatric exclusivity respect januvia janumet janumet xr provides six months exclusivity united states beyond expiration patents listed fdas orange book including exclusivity key patent protection extends january company anticipates sales januvia janumet united states decline significantly loss market exclusivity however januvia janumet janumet xr contain sitagliptin phosphate monohydrate company another patent covering certain phosphate salt polymorphic forms sitagliptin determined valid would preclude generic manufacturers making sitagliptin phosphate salt polymorphic forms patent inclusive pediatric exclusivity expires saltpolymorph patent par pharmaceutical filed suit company us district court district new jersey seeking declaratory judgment invalidity saltpolymorph patent response company filed patent infringement lawsuit us district court district delaware par pharmaceutical additional companies also indicated intent market generic versions januvia janumet janumet xr following expiration key patent protection prior expiration saltpolymorph patent later granted patent owned company covering janumet formulation inclusive pediatric exclusivity expires company also filed patent infringement lawsuit mylan northern district west virginia judicial panel multidistrict litigation entered order transferring companys lawsuit mylan us district court district delaware coordinated consolidated pretrial proceedings cases pending district us district court district delaware scheduled lawsuits single threeday trial invalidity issues october court scheduled separate oneday trials infringement issues november january extent trials necessary companys case mylan us district court northern district west virginia conditionally scheduled threeday trial december issues company settled nine generic companies providing generic companies bring products market may earlier certain circumstances additionally mylan filed petition inter partes review ipr united states patent trademark office uspto seeking invalidity claims saltpolymorph patent manufacturers joined uspto instituted ipr proceedings may finding reasonable likelihood challenged claims valid trial held february final decision expected may challenges successful unchallenged claims saltpolymorph patent remain valid subject court proceedings described germany two generic companies sought revocation supplementary protection certificate spc janumet generic companies successful janumet could lose market exclusivity germany early july challenges janumet spc also occurred portugal finland could occur european countries nexplanon june microspherix llc microspherix sued company us district court district new jersey asserting manufacturing use sale importation nexplanon infringed several microspherixs patents claim radioopaque implantable drug delivery devices microspherix claiming damages september patents expire may company brought ipr proceedings uspto successfully stayed district court action uspto invalidated claims asserted company company appealed decisions finding claims valid court appeals federal circuit affirmed usptos decisions matter longer stayed district court company currently litigating invalidity noninfringement remaining asserted claims litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial condition results operations cash flows either individually aggregate table contents legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial condition results operations liquidity company company taken active role identifying accruing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year table contents equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december issuances primarily reflect activity sharebased compensation plans company entered accelerated share repurchase asr agreements two thirdparty financial institutions dealers asr agreements merck agreed purchase billion mercks common stock total initial delivery million shares mercks common stock based thencurrent market price made dealers merck payments billion made merck dealers funded existing cash investments well shortterm borrowings upon settlement asr agreements merck received additional million shares determined average daily volume weightedaverage price mercks common stock term asr program less negotiated discount bringing total shares received merck program million sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees addition employees nonemployee directors may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders december million shares collectively authorized future grants companys sharebased compensation plans awards settled treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest one third year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus psus dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period subject terms applicable awards psu awards generally vest three years rsu awards generally vest onethird year threeyear period total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield risk table contents free interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree interest rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited outstanding december exercisable december additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses table contents pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plans consisted following components pension benefits us international postretirement benefits years ended december service cost interest cost expected return plan assets amortization unrecognized prior service cost net loss gain amortization termination benefits curtailments settlements net periodic benefit cost credit changes net periodic benefit cost year year pension plans largely attributable changes discount rate affecting net loss amortization connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension postretirement benefit plans settlements recorded certain us international pension plans reflected table components net periodic benefit cost credit service cost component included income expense net see note exception certain amounts termination benefits curtailments settlements recorded restructuring costs event giving rise termination benefits curtailment settlement related restructuring actions noted table contents obligations funded status summarized information changes plan assets benefit obligations funded status amounts recorded december follows pension benefits postretirement us international benefits fair value plan assets january actual return plan assets company contributions effects exchange rate changes benefits paid settlements fair value plan assets december benefit obligation january service cost interest cost actuarial losses gains benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities actuarial losses gains primarily reflect changes discount rates december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans table contents information related funded status selected pension plans december follows us international pension plans projected benefit obligation excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately companys pension investments categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using level level level nav total level level level nav total us pension plans cash cash equivalents investment funds developed markets equities emerging markets equities mortgage assetbacked securities government agency obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments plan assets fair value international pension plans cash cash equivalents investment funds developed markets equities government agency obligations emerging markets equities corporate obligations fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy nav amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total us pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales net balance december international pension plans balance january actual return plan assets relating assets still held december purchases sales net transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using level level level nav total level level level nav total cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations mortgage assetbacked securities equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy nav amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans table contents targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions expected contributions approximately million us pension plans approximately million international pension plans approximately million postretirement benefit plans expected benefit payments expected benefit payments follows international pension postretirement us pension benefits benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net periodic benefit cost average remaining service life employees following amounts reflected components oci pension plans postretirement us international benefit plans years ended december net loss gain arising period prior service cost credit arising period net loss gain amortization included benefit cost prior service credit amortization included benefit cost table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining us pension postretirement benefit plan international pension plan information follows us pension postretirement benefit plans international pension plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate interest crediting rate benefit obligation discount rate salary growth rate interest crediting rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis expected rate return plan developed considering longterm historical returns data current market conditions actual returns plan assets using reference information longterm return expectations asset category weightedaverage expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate savings plans company also maintains defined contribution savings plans united states company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange losses income investments equity securities net net periodic defined benefit plan credit cost service cost net includes net realized unrealized gains losses investments equity securities either owned directly ownership interests investment funds unrealized gains losses investments directly owned determined end reporting period ownership interests investment funds accounted one quarter lag net presented table includes million goodwill impairment charges related certain businesses healthcare services segment see note net includes gain million related settlement certain patent litigation income million related astrazenecas option exercise connection termination companys relationship astrazeneca lp azlp gain million resulting receipt milestone payment outlicensed migraine clinical development program net also includes million goodwill impairment charges related certain businesses healthcare services segment see note well million charges related writedown assets held sale fair value anticipation dissolution companys joint venture supera farma laboratorios sa brazil interest paid million million million taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising foreign earnings gilti foreignderived intangible income deduction rd tax credit tax settlements acquisition velosbio restructuring acquisition oncoimmune state taxes acquisitionrelated costs including amortization valuation allowances acquisition peloton tax cuts jobs act table contents tax cuts jobs act tcja enacted december company reflected impact tcja financial statements however since application certain provisions tcja remained subject interpretation certain instances company made reasonable estimates effects tcja since finalized resulted additional income tax expense companys remaining transition tax liability tcja reduced payments utilization foreign tax credits billion december million included income taxes payable remainder billion included noncurrent liabilities result transition tax tcja company longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability foreign withholding taxes would apply company remains indefinitely reinvested respect financial statement basis excess tax basis foreign subsidiaries determination deferred tax liability respect basis difference practicable foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates united states particularly ireland switzerland well singapore puerto rico operate tax incentive grants begin expire thereby yielding favorable impact effective tax rate compared us statutory rate towards end new reduced tax rate arrangement agreed switzerland certain newly active legal entities income taxes consisted years ended december domestic foreign taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state table contents deferred income taxes december consisted assets liabilities assets liabilities product intangibles licenses inventory related accelerated depreciation equity investments pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized assets deferred income taxes company net operating loss nol carryforwards several jurisdictions december million deferred taxes nol carryforwards relate foreign jurisdictions valuation allowances million established foreign nol carryforwards foreign deferred tax assets addition company million deferred tax assets relating various us tax credit carryforwards nol carryforwards expected fully utilized prior expiry income taxes paid billion billion billion respectively tax benefits relating stock option exercises million million million reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations balance december amounts reflects settlement irs discussed amount includes million related divestiture mercks consumer care business company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion table contents company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease approximately million next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures interest penalties associated uncertain tax positions amounted expense benefit million million million amounts reflect beneficial impacts various tax settlements including settlement discussed liabilities accrued interest penalties million million december respectively internal revenue service irs concluded examinations mercks us federal income tax returns result company required make payment million companys reserves unrecognized tax benefits years examination exceeded adjustments relating examination period therefore company recorded million net tax benefit net benefit reflects reductions reserves unrecognized tax benefits tax positions relating years examination partially offset additional reserves tax positions previously reserved irs currently conducting examinations companys tax returns years addition various state foreign tax examinations progress jurisdictions companys income tax returns open examination period earnings per share calculations earnings per share shares millions follows years ended december net income attributable merck co inc average common shares outstanding common shares issuable average common shares outstanding assuming dilution basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income loss changes aoci component follows employee cumulative accumulated benefit translation comprehensive derivatives investments plans adjustment income loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes adoption asu adoption asu balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes relates foreign currency cash flow hedges reclassified aoci sales represents net realized gains losses sales availableforsale investments reclassified aoci income expense net includes net amortization prior service cost actuarial gains losses included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table contents segment reporting companys operations principally managed products basis include two operating segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccine sales made us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers company previously healthcare services segment provided services solutions focused engagement health analytics clinical services improve value care delivered patients company divested remaining businesses segment first quarter company previously alliances segment primarily included activity companys relationship astrazeneca lp related sales nexium prilosec concluded table contents sales companys products follows years ended december us intl total us intl total us intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima emend vaccines gardasilgardasil proquadmmr iivarivax pneumovax rotateq vaqta hospital acute care bridion noxafil prevymis primaxin cancidas invanz cubicin zerbaxa immunology simponi remicade neuroscience belsomra virology isentressisentress hd zepatier cardiovascular zetia vytorin atozet alliance revenue adempas adempas diabetes januvia janumet womens health implanonnexplanon nuvaring diversified brands singulair cozaarhyzaar arcoxia nasonex follistim aq pharmaceutical total pharmaceutical segment sales animal health livestock companion animals total animal health segment sales segment sales total segment sales us plus international may equal total due rounding alliance revenue represents mercks share profits product sales net cost sales commercialization costs see note alliance revenue represents mercks share profits sales bayers marketing territories product sales net cost sales commercialization costs see note pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents sales nonreportable segments healthcare services fully divested first quarter alliances concluded primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales table contents consolidated sales geographic area derived follows years ended december united states europe middle east africa china japan asia pacific china japan latin america reconciliation segment profits income taxes follows years ended december segment profits pharmaceutical segment animal health segment segments total segment profits profits unallocated interest income interest expense depreciation amortization research development amortization purchase accounting adjustments restructuring costs charge related termination collaboration samsung unallocated net income taxes pharmaceutical segment profits comprised segment sales less standard costs well selling general administrative expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well selling general administrative expenses research development costs directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described research development expenses incurred merck research laboratories companys research development division focuses human healthrelated activities general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization purchase accounting adjustments allocated segments profits primarily comprised miscellaneous corporate profits well operating profits related thirdparty manufacturing sales unallocated net includes expenses corporate manufacturing cost centers goodwill intangible asset impairment charges gains losses sales businesses expense income related changes estimated fair value liabilities contingent consideration miscellaneous income expense items table contents equity income loss affiliates depreciation amortization included segment profits follows pharmaceutical animal health total year ended december included segment profits equity income loss affiliates depreciation amortization year ended december included segment profits equity income loss affiliates depreciation amortization year ended december included segment profits equity income loss affiliates depreciation amortization property plant equipment net geographic area located follows december united states europe middle east africa asia pacific china japan latin america china japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors stockholders merck co inc opinions financial statements internal control financial reporting audited accompanying consolidated balance sheet merck co inc subsidiaries company december related consolidated statements income comprehensive income equity cash flows three years period ended december including related notes collectively referred consolidated financial statements also audited companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso basis opinions companys management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report internal control financial reporting appearing item responsibility express opinions companys consolidated financial statements companys internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements table contents inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate critical audit matters critical audit matter communicated matter arising current period audit consolidated financial statements communicated required communicated audit committee relates accounts disclosures material consolidated financial statements ii involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matter providing separate opinion critical audit matter accounts disclosures relates customer discount accruals us medicaid managed care medicare part rebates described note consolidated financial statements company records certain variable consideration including discounts estimated time sale generally using expected value method amounts accrued aggregate customer discounts december us billion evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued certain discounts take form rebates amounts owed based upon definitive contractual agreements legal requirements private sector managed care public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers management uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision principal considerations determination performing procedures relating customer discount accruals us medicaid managed care medicare part rebates critical audit matter significant judgment management due significant measurement uncertainty involved developing provisions provisions include assumptions related changes price historical customer segment utilization mix pertaining forecasted customer claims may fully paid subsequent period turn led high degree auditor judgment subjectivity effort applying procedures related assumptions evaluating evidence obtained procedures addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating customer discount accruals us medicaid managed care medicare part rebates including managements controls assumptions used estimate corresponding rebate accruals procedures also included among others developing independent estimate rebate accruals utilizing third party data historical customer segment utilization mix us changes price terms specific rebate programs historical trend actual rebate claims paid ii comparing independent estimate rebate accruals recorded management iii testing actual rebate claims paid including evaluating claims consistency contractual terms companys rebate agreements pricewaterhousecoopers llp florham park new jersey february served companys auditor since table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective fourth quarter changes internal control financial reporting materially affected reasonably likely materially affect companys internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated table contents framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier robert davis chairman president executive vice president global services chief executive officer chief financial officer item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document required information compliance section securities exchange act applicable incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website wwwmerckcomcompany overviewcultureandvaluescodeofconductvaluesandstandards company intends disclose future amendments certain provisions code conduct waivers code conduct granted executive officers directors website within four business days following date amendment waiver every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related schedule director fees table director compensation table companys proxy statement annual meeting shareholders held may required information headings compensation benefits committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans merck us savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck co inc incentive stock plans merck co inc nonemployee directors stock option plan excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred merck co inc plan deferred payment directors compensation item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion proposal ratification appointment independent registered public accounting firm beginning caption preapproval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item